Coronary sinus cannulation

Information

  • Patent Grant
  • 11337594
  • Patent Number
    11,337,594
  • Date Filed
    Wednesday, April 18, 2018
    6 years ago
  • Date Issued
    Tuesday, May 24, 2022
    a year ago
Abstract
A method of cannulating a coronary sinus within a heart chamber includes deploying, from a catheter, an imaging hood to a deployed configuration by extending the imaging hood from a distal end of the catheter and radially expanding the imaging hood to define a constant deployed volume within an open area of the imaging hood. The method further includes positioning a contact edge of the imaging hood and the open area of the imaging hood in the deployed configuration over or upon an ostium of the coronary sinus, displacing an opaque fluid with a transparent fluid from the open area defined by the imaging hood and tissue surrounding the ostium, visualizing the ostium through the transparent fluid by viewing the ostium via an imaging element attached to an inner surface of the imaging hood, and introducing a guidewire through the imaging hood and into the ostium while under visual guidance.
Description
FIELD OF THE INVENTION

The present invention relates generally to medical devices used for accessing, visualizing, and/or treating regions of tissue within a body. More particularly, the present invention relates to systems and methods for accessing and/or cannulating a coronary sinus within a patient's heart.


BACKGROUND OF THE INVENTION

Conventional devices for visualizing interior regions of a body lumen are known. For example, ultrasound devices have been used to produce images from within a body in vivo. Ultrasound has been used both with and without contrast agents, which typically enhance ultrasound-derived images.


Other conventional methods have utilized catheters or probes having position sensors deployed Within the body lumen, such as the interior of a cardiac chamber. These types of positional sensors are typically used to determine the movement of a cardiac tissue surface or the electrical activity within the cardiac tissue. When a sufficient number of points have been sampled by the sensors, a “map” of the cardiac tissue may be generated.


Another conventional device utilizes an inflatable balloon which is typically introduced intravascularly in a deflated state and then inflated against the tissue region to be examined. Imaging is typically accomplished by an optical fiber or other apparatus such as electronic chips for viewing the tissue through the membrane(s) of the inflated balloon. Moreover, the balloon must generally be inflated for imaging. Other conventional balloons utilize a cavity or depression formed at a distal end of the inflated balloon. This cavity or depression is pressed against the tissue to be examined and is flushed with a clear fluid to provide a clear pathway through the blood.


However, such imaging balloons have many inherent disadvantages. For instance, such balloons generally require that the balloon be inflated to a relatively large size which may undesirably displace surrounding tissue and interfere with fine positioning of the imaging system against the tissue. Moreover, the working area created by such inflatable balloons are generally cramped and limited in size. Furthermore, inflated balloons may be susceptible to pressure changes in the surrounding fluid. For example, if the environment surrounding the inflated balloon undergoes pressure changes, e.g., during systolic and diastolic pressure cycles in a beating heart, the constant pressure change may affect the inflated balloon volume and its positioning to produce unsteady or undesirable conditions for optimal tissue imaging.


Accordingly, these types of imaging modalities are generally unable to provide desirable images useful for sufficient diagnosis and therapy of the endoluminal structure, due in part to factors such as dynamic forces generated by the natural movement of the heart. Moreover, anatomic structures within the body can occlude or obstruct the image acquisition process. Also, the presence and movement of opaque bodily fluids such as blood generally make in vivo imaging of tissue regions within the heart difficult.


Other external imaging modalities are also conventionally utilized. For example, computed tomography (CT) and magnetic resonance imaging (MRI) are typical modalities which are widely used to obtain images of body lumens such as the interior chambers of the heart. However, such imaging modalities fail to provide real-time imaging for intra-operative therapeutic procedures. Fluoroscopic imaging, for instance, is widely used to identify anatomic landmarks within the heart and other regions of the body. However, fluoroscopy fails to provide an accurate image of the tissue quality or surface and also fails to provide for instrumentation for performing tissue manipulation or other therapeutic procedures upon the visualized tissue regions. In addition, fluoroscopy provides a shadow of the intervening tissue onto a plate or sensor when it may be desirable to view the intraluminal surface of the tissue to diagnose pathologies or to perform some form of therapy on it.


Thus, a tissue imaging system which is able to provide real-time in vivo images of tissue regions within body lumens such as the heart through opaque media such as blood and which also provide instruments for therapeutic procedures upon the visualized tissue are desirable.


BRIEF SUMMARY OF THE INVENTION

A tissue imaging and manipulation apparatus that may be utilized for procedures within a body lumen, such as the heart, in which visualization of the surrounding tissue is made difficult, if not impossible, by medium contained within the lumen such as blood, is described below. Generally, such a tissue imaging and manipulation apparatus comprises an optional delivery catheter or sheath through which a deployment catheter and imaging hood may be advanced for placement against or adjacent to the tissue to be imaged.


The deployment catheter may define a fluid delivery lumen therethrough as well as an imaging, lumen within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, the imaging hood may be expanded into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field is defined by the imaging hood. The open area is the area within which the tissue region of interest may be imaged. The imaging hood may also define an atraumatic contact lip or edge for placement or abutment against the tissue region of interest. Moreover, the distal end of the deployment catheter or separate manipulatable catheters may be articulated through various controlling mechanisms such as push-pull wires manually or via computer control


The deployment catheter may also be stabilized relative to the tissue surface through various methods. For instance, inflatable stabilizing balloons positioned along a length of the catheter may be utilized, or tissue engagement anchors may be passed through or along the deployment catheter for temporary engagement of the underlying tissue.


In operation, after the imaging hood has been deployed, fluid may be pumped at a positive pressure through the fluid delivery lumen until the fluid fills the open area completely and displaces any blood from within the open area. The fluid may comprise any biocompatible fluid, e.g., saline, water, plasma, Fluorinert™, etc., which is sufficiently transparent to allow for relatively undistorted visualization through the fluid. The fluid may be pumped continuously or intermittently to allow for image capture by an optional processor which may be in communication with the assembly.


In an exemplary variation for imaging tissue surfaces within a heart chamber containing blood, the tissue imaging and treatment system may generally comprise a catheter body having a lumen defined therethrough, a visualization element disposed adjacent the catheter body, the visualization element having a field of view, a transparent fluid source in fluid communication with the lumen, and a barrier or membrane extendable from the catheter body to localize, between the visualization element and the field of view, displacement of blood by transparent fluid that flows from the lumen, and a piercing instrument translatable through the displaced blood for piercing into the tissue surface within the field of view.


The imaging hood may be formed into any number of configurations and the imaging assembly may also be utilized with any number of therapeutic tools which may be deployed through the deployment catheter.


More particularly in certain variations, the tissue visualization system may comprise components including the imaging hood, where the hood may further include a membrane having a main aperture and additional optional openings disposed over the distal end of the hood. An introducer sheath or the deployment catheter upon which the imaging hood is disposed may further comprise a steerable segment made of multiple adjacent links which are pivotably connected to one another and which may be articulated within a single plane or multiple planes. The deployment catheter itself may be comprised of a multiple lumen extrusion; such as a four-lumen catheter extrusion, which is reinforced with braided stainless steel fibers to provide structural support. The proximal end of the catheter may be coupled to a handle for manipulation and articulation of the system.


The apparatus and methods of use described herein relate to tissue visualization catheters that can locate and/or cannulate a morphological feature within a body lumen, such as the coronary sinus, with the ability to perform a variety of therapeutic tissue treatments under direct in vivo visualization thereafter.


In one example of use, the hood may be positioned along an initial location along the tissue wall within the heart chamber, e.g., the right atrium, of a patient's heart. The underlying tissue may be visualized, either directly through the hood or through an inflatable balloon positioned within the hood, to determine an initial location of the hood relative to the ostium of the coronary sinus. Either with the balloon inflated or omitted, the hood may be moved along the tissue surface while visualizing the underlying tissue until the coronary sinus ostium has been located. Visual confirmation of the ostium may be determined by the influx of blood into the hood or by the presence of a red spot in contrast to the surrounding tissue when viewed through the balloon.


In either case, with the location of the ostium realized, a guidewire or other instrument may be passed through the catheter and hood and directly into the ostium while under direct visual guidance. Moreover, apparatus and methods described herein may also be utilized with guidewires to facilitate delivery into the coronary sinus to eliminate repositioning of the device and/or repeating an entire sequence of operation, consequently improving procedure effectiveness and reducing procedure time.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A shows a side view of one variation of a tissue imaging apparatus during deployment from a sheath or delivery catheter.



FIG. 1B shows the deployed tissue imaging apparatus of FIG. 1A having an optionally expandable hood or sheath attached to an imaging and/or diagnostic catheter.



FIG. 1C shows an end view of a deployed imaging apparatus.



FIGS. 1D to 1F show the apparatus of FIGS. 1A to 1C with an additional lumen, e.g., for passage of a guidewire therethrough.



FIGS. 2A and 2B show one example of a deployed tissue imager positioned against or adjacent to the tissue to be imaged and a flow of fluid, such as saline, displacing blood from within the expandable hood.



FIG. 3A shows an articulatable imaging assembly which may be manipulated via push-pull wires or by computer control.



FIGS. 3B and 3C show steerable instruments, respectively, where an articulatable delivery catheter may be steered within the imaging hood or a distal portion of the deployment catheter itself may be steered.



FIGS. 4A to 4C show side and cross-sectional end views, respectively, of another variation having an off-axis imaging capability.



FIG. 5 shows an illustrative view of an example of a tissue imager advanced intravascularly within a heart for imaging tissue regions within an atrial chamber.



FIGS. 6A to 6C illustrate deployment catheters having one or more optional inflatable balloons or anchors for stabilizing the device during a procedure.



FIGS. 7A and 7B illustrate a variation of an anchoring mechanism such as a helical tissue piercing device for temporarily stabilizing the imaging hood relative to a tissue surface.



FIG. 7C shows another variation for anchoring the imaging hood having one or more tubular support members integrated with the imaging hood; each support members may define a lumen there though for advancing a helical tissue anchor within.



FIG. 8A shows an illustrative example of one variation of how a tissue imager may be utilized with an imaging device.



FIG. 8B shows a further illustration of a hand-held variation of the fluid delivery and tissue manipulation system.



FIGS. 9A to 9C illustrate an example of capturing several images of the tissue at multiple regions.



FIGS. 10A and 10B show charts illustrating how fluid pressure within the imaging hood may be coordinated with the surrounding blood pressure; the fluid pressure in the imaging hood may be coordinated with the blood pressure or it may be regulated based upon pressure feedback from the blood.



FIG. 11A shows a side view of another variation of a tissue imager having an imaging balloon within an expandable hood.



FIG. 11B shows another variation of a tissue imager utilizing a translucent or transparent imaging balloon.



FIG. 12A shows another variation in which a flexible expandable or distensible membrane may be incorporated within the imaging hood to alter the volume of fluid dispensed.



FIGS. 12B and 12C show another variation in which the imaging hood may be partially or selectively deployed from the catheter to alter the area of the tissue being visualized as well as the volume of the dispensed fluid.



FIGS. 13A and 13B show exemplary side and cross-sectional views, respectively, of another variation in which the injected fluid may be drawn back into the device for minimizing fluid input into a body being treated.



FIGS. 14A to 14D show various configurations and methods for configuring an imaging hood into a low-profile for delivery and/or deployment.



FIGS. 15A and 15B show an imaging hood having an helically expanding frame or support.



FIGS. 16A and 16B show another imaging hood having one or more hood support members, which are pivotably attached at their proximal ends to deployment catheter, integrated with a hood membrane.



FIGS. 17A and 17B show yet another variation of the imaging hood having at least two or more longitudinally positioned support members supporting the imaging hood membrane where the support members are movable relative to one another via a torquing or pulling or pushing force.



FIGS. 18A and 18B show another variation where a distal portion of the deployment catheter may have several pivoting members which form a tubular shape in its low profile configuration.



FIGS. 19A and 19B show another variation where the distal portion of deployment catheter may be fabricated from a flexible metallic or polymeric material to form a radially expanding hood.



FIGS. 20A and 20B show another variation where the imaging hood may be formed from a plurality of overlapping hood members which overlie one another in an overlapping pattern.



FIGS. 21A and 21B show another example of an expandable hood which is highly conformable against tissue anatomy with varying geography.



FIG. 22A shows yet another example of an expandable hood having a number of optional electrodes placed about the contact edge or lip of the hood for sensing tissue contact or detecting arrhythmias.



FIG. 22B shows another variation for conforming the imaging hood against the underlying tissue where an inflatable contact edge may be disposed around the circumference of the imaging hood.



FIG. 23 shows a variation of the system which may be instrumented with a transducer for detecting the presence of blood seeping back into the imaging hood.



FIGS. 24A and 24B show variations of the imaging hood instrumented with sensors for detecting various physical parameters; the sensors may be instrumented around the outer surface of the imaging hood and also within the imaging hood.



FIGS. 25A and 25B show a variation where the imaging hood may have one or more LEDs over the hood itself for providing illumination of the tissue to be visualized.



FIGS. 26A and 26B show another variation in which a separate illumination tool having one or more LEDs mounted thereon may be utilized within the imaging hood.



FIG. 27 shows one example of how a therapeutic tool may be advanced through the tissue imager for treating a tissue region of interest.



FIG. 28 shows another example of a helical therapeutic tool for treating the tissue region of interest.



FIG. 29 shows a variation of how a therapeutic tool may be utilized with an expandable imaging balloon.



FIGS. 30A and 30B show alternative configurations for therapeutic instruments which may be utilized; one variation is shown having an angled instrument arm and another variation is shown with an off-axis instrument arm.



FIGS. 31A to 31C show side and end views, respectively, of an imaging system which may be utilized with an ablation probe.



FIGS. 32A and 32B show side and end views, respectively, of another variation of the imaging hood with an ablation probe, where the imaging hood may be enclosed for regulating a temperature of the underlying tissue.



FIGS. 33A and 33B show an example in which the imaging fluid itself may be altered in temperature to facilitate various procedures upon the underlying tissue.



FIGS. 34A and 34B show an example of a laser ring generator which may be utilized with the imaging system and an example for applying the laser ring generator within the left atrium of a heart for treating atrial fibrillation.



FIGS. 35A to 35C show an example of an extendible cannula generally comprising an elongate tubular member which may be positioned within the deployment catheter during delivery and then projected distally through the imaging hood and optionally beyond.



FIGS. 36A and 36B show side and end views, respectively, of an imaging hood having one or more tubular support members integrated with the hood for passing instruments or tools therethrough for treatment upon the underlying tissue.



FIGS. 37A and 37B illustrate how an imaging device may be guided within a heart chamber to a region of interest utilizing a lighted probe positioned temporarily within, e.g., a lumen of the coronary sinus.



FIGS. 38A and 38B show an imaging hood having a removable disk-shaped member for implantation upon the tissue surface.



FIGS. 39A to 39C show one method for implanting the removable disk of FIGS. 38A and 38B.



FIGS. 40A and 40B illustrate an imaging hood having a deployable anchor assembly attached to the tissue contact edge and an assembly view of the anchors and the suture or wire connected to the anchors, respectively



FIGS. 41A to 41D show one method for deploying the anchor assembly of FIGS. 40A and 40B for closing an opening or wound.



FIG. 42 shows another variation in which the imaging system may be fluidly coupled to a dialysis unit for filtering a patient's blood.



FIGS. 43A and 43B show a variation of the deployment catheter having a first deployable hood and a second deployable hood positioned distal to the first hood; the deployment catheter may also have a side-viewing imaging element positioned between the first and second hoods for imaging tissue between the expanded hoods.



FIGS. 44A and 44B show side and end views, respectively, of a deployment catheter having a side-imaging balloon in an un-inflated low-profile configuration.



FIGS. 45A to 45C show side, top, and end views, respectively, of the inflated balloon of FIGS. 44A and 44B defining a visualization field in the inflated balloon.



FIGS. 46A and 46B show side and cross-sectional end views, respectively, for one method of use in visualizing a lesion upon a vessel wall within the visualization field of the inflated balloon from FIGS. 45A to 45C.



FIGS. 47A to 47C which show a hood having an inflatable circumferential balloon which may protrude distally from the hood to provide a wider viewing angle of the underlying contacted tissue.



FIG. 48 shows a side view of an example of how the field of view from the imaging element through the distally expanded balloon may be increased for imaging the tissue beyond contact lip.



FIG. 49 illustrates a fully inflated balloon pressed against the tissue surface where the contact lip is raised away from the tissue surface by the balloon to provide the expanded field of view through the balloon.



FIGS. 50A to 50E illustrate partial cross-sectional views of an example of a hood positioned upon the deployment catheter being articulated along the chamber tissue wall while visualizing the underlying tissue and locating and cannulating the coronary sinus ostium while under direct visual guidance.





DETAILED DESCRIPTION OF THE INVENTION

A tissue-imaging and manipulation apparatus described below is able to provide real-time images in vivo of tissue regions within a body lumen such as a heart, which is filled with blood flowing dynamically therethrough and is also able to provide intravascular tools and instruments for performing various procedures upon the imaged tissue regions. Such an apparatus may be utilized for many procedures, e.g., facilitating transseptal access to the left atrium, cannulating the coronary sinus, diagnosis of valve regurgitation/stenosis, valvuloplasty, atrial appendage closure, arrhythmogenic focus ablation, among other procedures.


One variation of a tissue access and imaging apparatus is shown in the detail perspective views of FIGS. 1A to 1C. As shown in FIG. 1A, tissue imaging and manipulation assembly 10 may be delivered intravascularly through, the patient's body in a low-profile configuration via a delivery catheter or sheath 14. In the case of treating tissue, such as the mitral valve located at the outflow tract of the left atrium of the heart, it is generally desirable to enter or access the left atrium while minimizing trauma to the patient. To non-operatively effect such access, one conventional approach involves puncturing the intra-atrial septum from the right atrial chamber to the left atrial chamber in a procedure commonly called a transseptal procedure or septostomy. For procedures such as percutaneous valve repair and replacement, transseptal access to the left atrial chamber of the heart may allow for larger devices to be introduced into the venous system than can generally be introduced percutaneously into the arterial system.


When the imaging and manipulation assembly 10 is ready to be utilized for imaging tissue, imaging hood 12 may be advanced relative to catheter 14 and deployed from a distal opening of catheter 14, as shown by the arrow. Upon deployment, imaging hood 12 may be unconstrained to expand or open into a deployed imaging configuration, as shown in FIG. 1B. Imaging hood 12 may be fabricated from a variety of pliable or conformable biocompatible material including but not limited to, e.g., polymeric, plastic, or woven materials. One example of a woven material is Kevlar® (E. I. du Pont de Nemours, Wilmington, Del.), which is an aramid and which can be made into thin, e.g., less than 0.001 in., materials which maintain enough integrity for such applications described herein. Moreover, the imaging hood 12 may be fabricated from a translucent or opaque material and in a variety of different colors to optimize or attenuate any reflected lighting from surrounding fluids or structures, i.e., anatomical or mechanical structures or instruments. In either case, imaging hood 12 may be fabricated into a uniform structure or a scaffold-supported structure, in which case a scaffold made of a shape memory alloy, such as Nitinol, or a spring steel, or plastic, etc., may be fabricated and covered with the polymeric, plastic, or woven material. Hence, imaging hood 12 may comprise any of a wide variety of barriers or membrane structures, as may generally be used to localize displacement of blood or the like from a selected volume of a body lumen or heart chamber. In exemplary embodiments, a volume within an inner surface 13 of imaging hood 12 will be significantly less than a volume of the hood 12 between inner surface 13 and outer surface 11.


Imaging hood 12 may be attached at interface 24 to a deployment catheter 16 which may be translated independently of deployment catheter or sheath 14. Attachment of interface 24 may be accomplished through any number of conventional methods. Deployment catheter 16 may define a fluid delivery lumen 18 as well as an imaging lumen 20 within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, imaging hood 12 may expand into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field 26 is defined by imaging hood 12. The open area 26 is the area within which the tissue region of interest may be imaged. Imaging hood 12 may also define an atraumatic contact lip or edge 22 for placement or abutment against the tissue region of interest. Moreover, the diameter of imaging hood 12 at its maximum fully deployed diameter, e.g., at contact lip or edge 22, is typically greater relative to a diameter of the deployment catheter 16 (although a diameter of contact lip or edge 22 may be made to have a smaller or equal diameter of deployment catheter 16). For instance, the contact edge diameter may range anywhere from 1 to 5 times (or even greater, as practicable) a diameter of deployment catheter 16. FIG. 1C shows an end view of the imaging hood 12 in its deployed configuration. Also shown are the contact lip or edge 22 and fluid delivery lumen 18 and imaging lumen 20.


The imaging and manipulation assembly 10 may additionally define a guidewire lumen therethrough, e.g., a concentric or eccentric lumen, as shown in the side and end views, respectively, of FIGS. 1D to 1F. The deployment catheter 16 may define guidewire lumen 19 for facilitating the passage of the system over or along a guidewire 17, which may be advanced intravascularly within a body lumen. The deployment catheter 16 may then be advanced over the guidewire 17, as generally known in the art.


In operation, after imaging hood 12 has been deployed, as in FIG. 1B, and desirably positioned against the tissue region to be imaged along contact edge 22, the displacing fluid may be pumped at positive pressure through fluid delivery lumen 18 until fluid fills open area 26 completely and displaces any fluid 28 from within open area 26. The displacing fluid flow may be laminarized to improve its clearing effect and to help prevent blood from re-entering the imaging hood 12. Alternatively, fluid flow may be started before the deployment takes place. The displacing fluid, also described herein as imaging fluid, may comprise any biocompatible fluid, e.g., saline, water, plasma, etc., which is sufficiently transparent to allow for relatively undistorted visualization through the fluid. Alternatively or additionally, any number of therapeutic drugs may be suspended within the fluid or may comprise the fluid itself which is pumped into open area 26 and which is subsequently passed into and through the heart and the patient body.


As seen in the example of FIGS. 2A and 2B, deployment catheter 16 may be manipulated to position deployed imaging hood 12 against or near the underlying tissue region of interest to be imaged, in this example a portion of annulus A of mitral valve MV within the left atrial chamber. As the surrounding blood 30 flows around imaging hood 12 and within open area 26 defined within imaging hood 12, as seen in FIG. 2A, the underlying annulus A is obstructed by the opaque blood 30 and is difficult to view through the imaging lumen 20. The translucent fluid 28, such as saline, may then be pumped through fluid delivery lumen 18, intermittently or continuously, until the blood 30 is at least partially, and preferably completely, displaced from within open area 26 by fluid 28, as shown in FIG. 2B.


Although contact edge 22 need not directly contact the underlying tissue, it is at least preferably brought into close proximity to the tissue such that the flow of clear fluid 28 from open area 26 may be maintained to inhibit significant backflow of blood 30 back into open area 26. Contact edge 22 may also be made of a soft elastomeric material such as certain soft grades of silicone or polyurethane, as typically known, to help contact edge 22 conform to an uneven or rough underlying anatomical tissue surface. Once the blood 30 has been displaced from imaging hood 12, an image may then be viewed of the underlying tissue through the clear fluid 30. This image may then be recorded or available for real-time viewing for performing a therapeutic procedure. The positive flow of fluid 28 may be maintained continuously to provide for clear viewing of the underlying tissue. Alternatively, the fluid 28 may be pumped temporarily or sporadically only until a clear view of the tissue is available to be imaged and recorded, at which point the fluid flow 28 may cease and blood 30 may be allowed to seep or flow back into imaging hood 12. This process may be repeated a number of times at the same tissue region or at multiple tissue regions.


In desirably positioning the assembly at various regions within the patient body, a number of articulation and manipulation controls may be utilized. For example, as shown in the articulatable imaging assembly 40 in FIG. 3A, one or more push-pull wires 42 may be routed through deployment catheter 16 for steering the distal end portion of the device in various directions 46 to desirably position the imaging hood 12 adjacent to a region of tissue to be visualized. Depending upon the positioning and the number of push-pull wires 42 utilized, deployment catheter 16 and imaging hood 12 may be articulated into any number of configurations 44. The push-pull wire or wires 42 may be articulated via their proximal ends from outside the patient body manually utilizing one or more controls. Alternatively, deployment catheter 16 may be articulated by computer control, as further described below.


Additionally or alternatively, an articulatable delivery catheter 48, which may be articulated via one or more push-pull wires and having an imaging lumen and one or more working lumens, may be delivered through the deployment catheter 16 and into imaging hood 12. With a distal portion of articulatable delivery catheter 48 within imaging hood 12, the clear displacing fluid may be pumped through delivery catheter 48 or deployment catheter 16 to clear the field within imaging hood 12. As shown in FIG. 3B, the articulatable delivery catheter 48 may be articulated within the imaging hood to obtain a better image of tissue adjacent to the imaging hood 12. Moreover, articulatable delivery catheter 48 may be articulated to direct an instrument or tool passed through the catheter 48, as described in detail below, to specific areas of tissue imaged through imaging hood 12 without having to reposition deployment catheter 16 and re-clear the imaging field within hood 12.


Alternatively, rather than passing an articulatable delivery catheter 48 through the deployment catheter 16, a distal portion of the deployment catheter 16 itself may comprise a distal end 49 which is articulatable within imaging hood 12, as shown in FIG. 3C. Directed imaging, instrument delivery, etc., may be accomplished directly through one or more lumens within deployment catheter 16 to specific regions of the underlying tissue imaged within imaging hood 12.


Visualization within the imaging hood 12 may be accomplished through an imaging lumen 20 defined through deployment catheter 16, as described above. In such a configuration, visualization is available in a straight-line manner, i.e., images are generated from the field distally along a longitudinal axis defined by the deployment catheter 16. Alternatively or additionally, an articulatable imaging assembly having a pivotable support member 50 may be connected to, mounted to, or otherwise passed through deployment catheter 16 to provide for visualization off-axis relative to the longitudinal axis defined by deployment catheter 16, as shown in FIG. 4A. Support member 50 may have an imaging element 52, e.g., a CCD or CMOS imager or optical fiber, attached at its distal end with its proximal end connected to deployment catheter 16 via a pivoting connection 54.


If one or more optical fibers are utilized for imaging, the optical fibers 58 may be passed through deployment catheter 16, as shown in the cross-section of FIG. 4B, and routed through the support member 50. The use of optical fibers 58 may provide for increased diameter sizes of the one or several lumens 56 through deployment catheter 16 for the passage of diagnostic and/or therapeutic tools therethrough. Alternatively, electronic chips, such as a charge coupled device (CCD) or a CMOS imager, which are typically known, may be utilized in place of the optical fibers 58, in which case the electronic imager may be positioned in the distal portion of the deployment catheter 16 with electric wires being routed proximally through the deployment catheter 16. Alternatively, the electronic imagers may be wirelessly coupled to a receiver for the wireless transmission of images. Additional optical fibers or light emitting diodes (LEDs) can be used to provide lighting for the image or operative theater, as described below in further detail. Support member 50 may be pivoted via connection 54 such that the member 50 can be positioned in a low-profile configuration within channel or groove 60 defined in a distal portion of catheter 16, as shown in the cross-section of FIG. 4C. During intravascular delivery of deployment catheter 16 through the patient body, support member 50 can be positioned within channel or groove 60 with imaging hood 12 also in its low-profile configuration. During visualization, imaging hood 12 may be expanded into its deployed configuration and support member 50 may be deployed into its off-axis configuration for imaging the tissue adjacent to hood 12, as in FIG. 4A. Other configurations for support member 50 for off-axis visualization may be utilized, as desired.



FIG. 5 shows an illustrative cross-sectional view of a heart H having tissue regions of interest being viewed via an imaging assembly 10. In this example, delivery catheter assembly 70 may be introduced percutaneously into the patient's vasculature and advanced through the superior vena cava SVC and into the right atrium RA. The delivery catheter or sheath 72 may be articulated through the atrial septum AS and into the left atrium LA for viewing or treating the tissue, e.g., the annulus A, surrounding the mitral valve MV. As shown, deployment catheter 16 and imaging hood 12 may be advanced out of delivery catheter 72 and brought into contact or in proximity to the tissue region of interest. In other examples, delivery catheter assembly 70 may be advanced through the inferior vena cava IVC, if so desired. Moreover, other regions of the heart H, e.g., the right ventricle RV or left ventricle LV, may also be accessed and imaged or treated by imaging assembly 10.


In accessing regions of the heart H or other parts of the body, the delivery catheter or sheath 14 may comprise a conventional intra-vascular catheter or an endoluminal delivery device. Alternatively, robotically-controlled delivery catheters may also be optionally utilized with the imaging assembly described herein, in which case a computer-controller 74 may be used to control the articulation and positioning of the delivery catheter 14. An example of a roboticaily-controlled delivery catheter which may be utilized is described in further detail in US Pat. Pub. 2002/0087169 A1 to Brock et al, entitled “Flexible instrument”, which is incorporated herein by reference in its entirety. Other robotically-controlled delivery catheters manufactured by Hansen Medical, Inc. (Mountain View, Calif.) may also be utilized with the delivery catheter 14.


To facilitate stabilization of the deployment catheter 16 during a procedure, one or more inflatable balloons or anchors 76 may be positioned along the length of catheter 16, as shown in FIG. 6A. For example, when utilizing a transseptal approach across the atrial septum AS into the left atrium LA, the inflatable balloons 76 may be inflated from a low-profile into their expanded configuration to temporarily anchor or stabilize the catheter 16 position relative to the heart H. FIG. 6B shows a first balloon 78 inflated while FIG. 6C also shows a second balloon 80 inflated proximal to the first balloon 78. In such a configuration, the septal wall AS may be wedged or sandwiched between the balloons 78, 80 to temporarily stabilize the catheter 16 and imaging hood 12. A single balloon 78 or both balloons 78, 80 may be used. Other alternatives may utilize expandable mesh members, malecots, or any other temporary expandable structure. After a procedure has been accomplished, the balloon assembly 76 may be deflated or re-configured into a low-profile for removal of the deployment catheter 16.


To further stabilize a position of the imaging hood 12 relative to a tissue surface to be imaged, various anchoring mechanisms may be optionally employed for temporarily holding the imaging hood 12 against the tissue. Such anchoring mechanisms may be particularly useful for imaging tissue which is subject to movement, e.g., when imaging tissue within the chambers of a beating heart. A tool delivery catheter 82 having at least one instrument lumen and an optional visualization lumen may be delivered through deployment catheter 16 and into an expanded imaging hood 12. As the imaging hood 12 is brought into contact against a tissue surface T to be examined, anchoring mechanisms such as a helical tissue piercing device 84 may be passed through the tool delivery catheter 82, as shown in FIG. 7A, and into imaging hood 12.


The helical tissue engaging device 84 may be torqued from its proximal end outside the patient body to temporarily anchor itself into the underlying tissue surface T. Once embedded within the tissue T, the helical tissue engaging device 84 may be pulled proximally relative to deployment catheter 16 while the deployment catheter 16 and imaging hood 12 are pushed distally, as indicated by the arrows in FIG. 7B, to gently force the contact edge or lip 22 of imaging hood against the tissue T. The positioning of the tissue engaging device 84 may be locked temporarily relative to the deployment catheter 16 to ensure secure positioning of the imaging hood 12 during a diagnostic or therapeutic procedure within the imaging hood 12. After a procedure, tissue engaging device 84 may be disengaged from the tissue by torquing its proximal end in the opposite direction to remove the anchor form the tissue T and the deployment catheter 16 may be repositioned to another region of tissue where the anchoring process may be repeated or removed from the patient body. The tissue engaging device 84 may also be constructed from other known tissue engaging devices such as vacuum-assisted engagement or grasper-assisted engagement tools, among others.


Although a helical anchor 84 is shown, this is intended to be illustrative and other types of temporary anchors may be utilized, e.g., hooked or barbed anchors, graspers, etc. Moreover, the tool delivery catheter 82 may be omitted entirely and the anchoring device may be delivered directly through a lumen defined through the deployment catheter 16.


In another variation where the tool delivery catheter 82 may be omitted entirely to temporarily anchor imaging hood 12, FIG. 7C shows an imaging hood 12 having one or more tubular support members 86, e.g., four support members 86 as shown, integrated with the imaging hood 12. The tubular support members 86 may define lumens therethrough each having helical tissue engaging devices 88 positioned within. When an expanded imaging hood 12 is to be temporarily anchored to the tissue, the helical tissue engaging devices 88 may be urged distally to extend from imaging hood 12 and each may be torqued from its proximal end to engage the underlying tissue T. Each of the helical tissue engaging devices 88 may be advanced through the length of deployment catheter 16 or they may be positioned within tubular support members 86 during the delivery and deployment of imaging hood 12. Once the procedure within imaging hood 12 is finished, each of the tissue engaging devices 88 may be disengaged from the tissue and the imaging hood 12 may be repositioned to another region of tissue or removed from the patient body.


An illustrative example is shown in FIG. 8A of a tissue imaging assembly connected to a fluid delivery system 90 and to an optional processor 98 and image recorder and/or viewer 100. The fluid delivery system 90 may generally comprise a pump 92 and an optional valve 94 for controlling the flow rate of the fluid into the system. A fluid reservoir 96, fluidly connected to pump 92, may hold the fluid to be pumped through imaging hood 12. An optional central processing unit or processor 98 may be in electrical communication with fluid delivery system 90 for controlling flow parameters such as the flow rate and/or velocity of the pumped fluid. The processor 98 may also be in electrical communication with an image recorder and/or viewer 100 for directly viewing the images of tissue received from within imaging hood 12. Imager recorder and/or viewer 100 may also be used not only to record the image but also the location of the viewed tissue region, if so desired.


Optionally, processor 98 may also be utilized to coordinate the fluid flow and the image capture. For instance, processor 98 may be programmed to provide for fluid flow from reservoir 96 until the tissue area has been displaced of blood to obtain a clear image. Once the image has been determined to be sufficiently clear, either visually by a practitioner or by computer, an image of the tissue may be captured automatically by recorder 100 and pump 92 may be automatically stopped or slowed by processor 98 to cease the fluid flow into the patient. Other variations for fluid delivery and image capture are, of course, possible and the aforementioned configuration is intended only to be illustrative and not limiting.



FIG. 8B shows a further illustration of a hand-held variation of the fluid delivery and tissue manipulation system 110. In this variation, system 110 may have a housing or handle assembly 112 which can be held or manipulated by the physician from outside the patient body. The fluid reservoir 114, shown in this variation as a syringe, can be fluidly coupled to the handle assembly 112 and actuated via a pumping mechanism 116, e.g., lead screw. Fluid reservoir 114 may be a simple reservoir separated from the handle assembly 112 and fluidly coupled to handle assembly 112 via one or more tubes. The fluid flow rate and other mechanisms may be metered by the electronic controller 118.


Deployment of imaging hood 12 may be actuated by a hood deployment switch 120 located on the handle assembly 112 while dispensation of the fluid from reservoir 114 may be actuated by a fluid deployment switch 122, which can be electrically coupled to the controller 118. Controller 118 may also be electrically coupled to a wired or wireless antenna 124 optionally integrated with the handle assembly 112, as shown in the figure. The wireless antenna 124 can be used to wirelessly transmit images captured from the imaging hood 12 to a receiver, e.g., via Bluetooth® wireless technology (Bluetooth SIG, Inc., Bellevue, Wash.), RF, etc., for viewing on a monitor 128 or for recording for later viewing.


Articulation control of the deployment catheter 16, or a delivery catheter or sheath 14 through which the deployment catheter 16 may be delivered, may be accomplished by computer control, as described above, in which case an additional controller may be utilized with handle assembly 112. In the case of manual articulation, handle assembly 112 may incorporate one or more articulation controls 126 for manual manipulation of the position of deployment catheter 16. Handle assembly 112 may also define one or more instrument ports 130 through which a number of intravascular tools may be passed for tissue manipulation and treatment within imaging hood 12, as described further below. Furthermore, in certain procedures, fluid or debris may be sucked into imaging hood 12 for evacuation from the patient body by optionally fluidly coupling a suction pump 132 to handle assembly 112 or directly to deployment catheter 16.


As described above, fluid may be pumped continuously into imaging hood 12 to provide for clear viewing of the underlying tissue. Alternatively, fluid may be pumped temporarily or sporadically only until a clear view of the tissue is available to be imaged and recorded, at which point the fluid flow may cease and the blood may be allowed to seep or flow back into imaging hood 12. FIGS. 9A to 9C illustrate an example of capturing several images of the tissue at multiple regions. Deployment catheter 16 may be desirably positioned and imaging hood 12 deployed and brought into position against a region of tissue to be imaged, in this example the tissue surrounding a mitral valve MV within the left atrium of a patient's heart. The imaging hood 12 may be optionally anchored to the tissue, as described above, and then cleared by pumping the imaging fluid into the hood 12. Once sufficiently clear, the tissue may be visualized and the image captured by control electronics 118. The first captured image 140 may be stored and/or transmitted wirelessly 124 to a monitor 128 for viewing by the physician, as shown in FIG. 9A.


The deployment catheter 16 may be then repositioned to an adjacent portion of mitral valve MV, as shown in FIG. 9B, where the process may be repeated to capture a second image 142 for viewing and/or recording. The deployment catheter 16 may again be repositioned to another region of tissue, as shown in FIG. 9C, where a third image 144 may be captured for viewing and/or recording. This procedure may be repeated as many times as necessary for capturing a comprehensive image of the tissue surrounding mitral valve MV, or any other tissue region. When the deployment catheter 16 and imaging hood 12 is repositioned from tissue region to tissue region, the pump may be stopped during positioning and blood or surrounding fluid may be allowed to enter within imaging hood 12 until the tissue is to be imaged, where the imaging hood 12 may be cleared, as above.


As mentioned above, when the imaging hood 12 is cleared by pumping the imaging fluid within for clearing the blood or other bodily fluid, the fluid may be pumped continuously to maintain the imaging fluid within the hood 12 at a positive pressure or it may be pumped under computer control for slowing or stopping the fluid flow into the hood 12 upon detection of various parameters or until a clear image of the underlying tissue is obtained. The control electronics 118 may also be programmed to coordinate the fluid flow into the imaging hood 12 with various physical parameters to maintain a clear image within imaging hood 12.


One example is shown in FIG. 10A which shows a chart 150 illustrating how fluid pressure within the imaging hood 12 may be coordinated with the surrounding blood pressure. Chart 150 shows the cyclical blood pressure 156 alternating between diastolic pressure 152 and systolic pressure 154 over time T due to the beating motion of the patient heart. The fluid pressure of the imaging fluid, indicated by plot 160, within imaging hood 12 may be automatically timed to correspond to the blood pressure changes 160 such that an increased pressure is maintained within imaging hood 12 which is consistently above the blood pressure 156 by a slight increase ΔP, as illustrated by the pressure difference at the peak systolic pressure 158. This pressure difference, ΔP, may be maintained within imaging hood 12 over the pressure variance of the surrounding blood pressure to maintain a positive imaging fluid pressure within imaging hood 12 to maintain a clear view of the underlying tissue. One benefit of maintaining a constant ΔP is a constant flow and maintenance of a clear field.



FIG. 10B shows a chart 162 illustrating another variation for maintaining a clear view of the underlying tissue where one or more sensors within the imaging hood 12, as described in further detail below, may be configured to sense pressure changes within the imaging hood 12 and to correspondingly increase the imaging fluid pressure within imaging hood 12. This may result in a time delay, ΔT, as illustrated by the shifted fluid pressure 160 relative to the cycling blood pressure 156, although the time delays ΔT may be negligible in maintaining the clear image of the underlying tissue. Predictive software algorithms can also be used to substantially eliminate this time delay by predicting when the next pressure wave peak will arrive and by increasing the pressure ahead of the pressure wave's arrival by an amount of time equal to the aforementioned time delay to essentially cancel the time delay out.


The variations in fluid pressure within imaging hood 12 may be accomplished in part due to the nature of imaging hood 12. An inflatable balloon, which is conventionally utilized for imaging tissue, may be affected by the surrounding blood pressure changes. On the other hand, an imaging hood 12 retains a constant volume therewithin and is structurally unaffected by the surrounding blood pressure changes, thus allowing for pressure increases therewithin. The material that hood 12 is made from may also contribute to the manner in which the pressure is modulated within this hood 12. A stiffer hood material, such as high durometer polyurethane or Nylon, may facilitate the maintaining of an open hood when deployed. On the other hand, a relatively lower durometer or softer material, such as a low durometer PVC or polyurethane, may collapse from the surrounding fluid pressure and may not adequately maintain a deployed or expanded hood.


Turning now to the imaging hood, other variations of the tissue imaging assembly may be utilized, as shown in FIG. 11A, which shows another variation comprising an additional imaging balloon 172 within an imaging hood 174. In this variation, an expandable balloon 172 having a translucent skin may be positioned within imaging hood 174. Balloon 172 may be made from any distensible biocompatible material having sufficient translucent properties which allow for visualization therethrough. Once the imaging hood 174 has been deployed against the tissue region of interest, balloon 172 may be filled with a fluid, such as saline, or less preferably a gas, until balloon 172 has been expanded until the blood has been sufficiently displaced. The balloon 172 may thus be expanded proximal to or into contact against the tissue region to be viewed. The balloon 172 can also be filled with contrast media to allow it to be viewed on fluoroscopy to aid in its positioning. The imager, e.g., fiber optic, positioned within deployment catheter 170 may then be utilized to view the tissue region through the balloon 172 and any additional fluid which may be pumped into imaging hood 174 via one or more optional fluid ports 176, which may be positioned proximally of balloon 172 along a portion of deployment catheter 170. Alternatively, balloon 172 may define one or more holes over its surface which allow for seepage or passage of the fluid contained therein to escape and displace the blood from within imaging hood 174.



FIG. 11B shows another alternative in which balloon 180 may be utilized alone. Balloon 180, attached to deployment catheter 178, may be filled with fluid, such as saline or contrast media, and preferably allowed to come into direct contact with the tissue region to be imaged.



FIG. 12A shows another alternative in which deployment catheter 16 incorporates imaging hood 12, as above, and includes an additional flexible membrane 182 within imaging hood 12. Flexible membrane 182 may be attached at a distal end of catheter 16 and optionally at contact edge 22. Imaging hood 12 may be utilized, as above, and membrane 182 may be deployed from catheter 16 in vivo or prior to placing catheter 16 within a patient to reduce the volume within imaging hood 12. The volume may be reduced or minimized to reduce the amount of fluid dispensed for visualization or simply reduced depending upon the area of tissue to be visualized.



FIGS. 12B and 12C show yet another alternative in which imaging hood 186 may be withdrawn proximally within deployment catheter 184 or deployed distally from catheter 186, as shown, to vary the volume of imaging hood 186 and thus the volume of dispensed fluid. Imaging hood 186 may be seen in FIG. 12B as being partially deployed from, e.g., a circumferentially defined lumen within catheter 184, such as annular lumen 188. The underlying tissue may be visualized with imaging hood 186 only partially deployed. Alternatively, imaging hood 186′ may be fully deployed, as shown in FIG. 12C, by urging hood 186′ distally out from annular lumen 188. In this expanded configuration, the area of tissue to be visualized may be increased as hood 186′ is expanded circumferentially.



FIGS. 13A and 13B show perspective and cross-sectional side views, respectively, of yet another variation of imaging assembly which may utilize a fluid suction system for minimizing the amount of fluid injected into the patient's heart or other body lumen during tissue visualization. Deployment catheter 190 in this variation may define an inner tubular member 196 which may be integrated with deployment catheter 190 or independently translatable. Fluid delivery lumen 198 defined through member 196 may be fluidly connected to imaging hood 192, which may also define one or more open channels 194 over its contact lip region. Fluid pumped through fluid delivery lumen 198 may thus fill open area 202 to displace any blood or other fluids or objects therewithin. As the clear fluid is forced out of open area 202, it may be sucked or drawn immediately through one or more channels 194 and back into deployment catheter 190. Tubular member 196 may also define one or more additional working channels 200 for the passage of any tools or visualization devices.


In deploying the imaging hood in the examples described herein, the imaging hood may take on any number of configurations when positioned or configured for a low-profile delivery within the delivery catheter, as shown in the examples of FIGS. 14A to 14D. These examples are intended to be illustrative and are not intended to be limiting in scope. FIG. 14A shows one example in which imaging hood 212 may be compressed within catheter 210 by folding hood 212 along a plurality of pleats. Hood 212 may also comprise scaffolding or frame 214 made of a super-elastic or shape memory material or alloy, e.g., Nitinol, Elgiloy, shape memory polymers, electroactive polymers, or a spring stainless steel. The shape memory material may act to expand or deploy imaging hood 212 into its expanded configuration when urged in the direction of the arrow from the constraints of catheter 210.



FIG. 14B shows another example in which imaging hood 216 may be expanded or deployed, from catheter 210 from a folded and overlapping configuration. Frame or scaffolding 214 may also be utilized in this example. FIG. 14C shows yet another example in which imaging hood 218 may be rolled, inverted, or everted upon itself for deployment. In yet another example, FIG. 14D shows a configuration in which imaging hood 220 may be fabricated from an extremely compliant material which allows for hood 220 to be simply compressed into a low-profile shape. From this low-profile compressed shape, simply releasing hood 220 may allow for it to expand into its deployed configuration, especially if a scaffold or frame of a shape memory or superelastic material, e.g., Nitinol, is utilized in its construction.


Another variation for expanding the imaging hood is shown in FIGS. 15A and 15B which illustrates an helically expanding frame or support 230. In its constrained low-profile configuration, shown in FIG. 15A, helical frame 230 may be integrated with the imaging hood 12 membrane. When free to expand, as shown in FIG. 15B, helical frame 230 may expand into a conical or tapered shape. Helical frame 230 may alternatively be made out of heat-activated Nitinol to allow it to expand upon application of a current.



FIGS. 16A and 16B show yet another variation in which imaging hood 12 may comprise one or more hood support members 232 integrated with the hood membrane. These longitudinally attached support members 232 may be pivotably attached at their proximal ends to deployment catheter 16. One or more pullwires 234 may be routed through the length of deployment catheter 16 and extend through one or more openings 238 defined in deployment catheter 16 proximally to imaging hood 12 into attachment with a corresponding support member 232 at a pullwire attachment point 236. The support members 232 may be fabricated from a plastic or metal, such as stainless steel. Alternatively, the support members 232 may be made from a superelastic or shape memory alloy, such as Nitinol, which may self-expand into its deployed configuration without the use or need of pullwires. A heat-activated Nitinol may also be used which expands upon the application of thermal energy or electrical energy. In another alternative, support members 232 may also be constructed as inflatable lumens utilizing, e.g., PET balloons. From its low-profile delivery configuration shown in FIG. 16A, the one or more pullwires 234 may be tensioned from their proximal ends outside the patient body to pull a corresponding support member 232 into a deployed configuration, as shown in FIG. 16B, to expand imaging hood 12. To reconfigure imaging hood 12 back into its low profile, deployment catheter 16 may be pulled proximally into a constraining catheter or the pullwires 234 may be simply pushed distally to collapse imaging hood 12.



FIGS. 17A and 17B show yet another variation of imaging hood 240 having at least two or more longitudinally, positioned support members 242 supporting the imaging hood membrane. The support members 242 each have cross-support members 244 which extend diagonally between and are pivotably attached to the support members 242. Each of the cross-support members 244 may be pivotably attached to one another where they intersect between the support members 242. A jack or screw member 246 may be coupled to each cross-support member 244 at this intersection point and a torquing member, such as a torqueable wire 248, may be coupled to each jack or screw member 246 and extend proximally through deployment catheter 16 to outside the patient body. From outside the patient body, the torqueable wires 248 may be torqued to turn the jack or screw member 246 which in turn urges the cross-support members 244 to angle relative to one another and thereby urge the support members 242 away from one another. Thus, the imaging hood 240 may be transitioned from its low-profile, shown in FIG. 17A, to its expanded profile, shown in FIG. 17B, and back into its low-profile by torquing wires 248.



FIGS. 18A and 18B show yet another variation on the imaging hood and its deployment. As shown, a distal portion of deployment catheter 16 may have several pivoting members 250, e.g., two to four sections, which form a tubular shape in its low profile configuration, as shown in FIG. 18A. When pivoted radially about deployment catheter 16, pivoting members 250 may open into a deployed configuration having distensible or expanding membranes 252 extending over the gaps in-between the pivoting members 250, as shown in FIG. 18B. The distensible membrane 252 may be attached to the pivoting members 250 through various methods, e.g., adhesives, such that when the pivoting members 250 are fully extended into a conical shape, the pivoting members 250 and membrane 252 form a conical shape for use as an imaging hood. The distensible membrane 252 may be made out of a porous material such as a mesh or PTFE or out of a translucent or transparent polymer such as polyurethane, PVC, Nylon, etc.



FIGS. 19A and 19B show yet another variation where the distal portion of deployment catheter 16 may be fabricated from a flexible metallic or polymeric material to form a radially expanding hood 254. A plurality of slots 256 may be formed in a uniform pattern over the distal portion of deployment catheter 16, as shown in FIG. 19A. The slots 256 may be formed in a pattern such that when the distal portion is urged radially open, utilizing any of the methods described above, a radially expanded and conically-shaped hood 254 may be formed by each of the slots 256 expanding into an opening, as shown in FIG. 19B. A distensible membrane 258 may overlie the exterior surface or the interior surface of the hood 254 to form a fluid-impermeable hood 254 such that the hood 254 may be utilized as an imaging hood. Alternatively, the distensible membrane 258 may alternatively be formed in each opening 258 to form the fluid-impermeable hood 254. Once the imaging procedure has been completed, hood 254 may be retracted into its low-profile configuration.


Yet another configuration for the imaging hood may be seen in FIGS. 20A and 20B where the imaging hood may be formed from a plurality of overlapping hood members 260 which overlie one another in an overlapping pattern. When expanded, each of the hood members 260 may extend radially outward relative to deployment catheter 16 to form a conically-shaped imaging hood, as shown in FIG. 20B. Adjacent hood members 260 may overlap one another along an overlapping interface 262 to form a fluid-retaining surface within the imaging hood. Moreover, the hood members 260 may be made from any number of biocompatible materials, e.g., Nitinol, stainless steel, polymers, etc., which are sufficiently strong to optionally retract surrounding tissue from the tissue region of interest.


Although it is generally desirable to have an imaging hood contact against a tissue surface in a normal orientation, the imaging hood may be alternatively configured to contact the tissue surface at an acute angle. An imaging hood configured for such contact against tissue may also be especially suitable for contact against tissue surfaces having an unpredictable or uneven anatomical geography. For instance, as shown in the variation of FIG. 21A, deployment catheter 270 may have an imaging hood 272 that is configured to be especially compliant. In this variation, imaging hood 272 may be comprised of one or more sections 274 that are configured to fold or collapse, e.g., by utilizing a pleated surface. Thus, as shown in FIG. 21B, when imaging hood 272 is contacted against uneven tissue surface T, sections 274 are able to conform closely against the tissue. These sections 274 may be individually collapsible by utilizing an accordion style construction to allow conformation, e.g., to the trabeculae in the heart or the uneven anatomy that may be found inside the various body lumens.


In yet another alternative, FIG. 22A shows another variation in which an imaging hood 282 is attached to deployment catheter 280. The contact lip or edge 284 may comprise one or more electrical contacts 286 positioned circumferentially around contact edge 284. The electrical contacts 286 may be configured to contact the tissue and indicate affirmatively whether tissue contact was achieved, e.g., by measuring the differential impedance between blood and tissue. Alternatively, a processor, e.g., processor 98, in electrical communication with contacts 286 may be configured to determine what type of tissue is in contact with electrical contacts 286. In yet another alternative, the processor 98 may be configured to measure any electrical activity that may be occurring in the underlying tissue, e.g., accessory pathways, for the purposes of electrically mapping the cardiac tissue and subsequently treating, as described below, any arrhythmias which may be detected.


Another variation for ensuring contact between imaging hood 282 and the underlying tissue may be seen in FIG. 22B. This variation may have an inflatable contact edge 288 around the circumference of imaging hood 282. The inflatable contact edge 288 may be inflated with a fluid or gas through inflation lumen 289 when the imaging hood 282 is to be placed against a tissue surface having an uneven or varied anatomy. The inflated circumferential surface 288 may provide for continuous contact over the hood edge by conforming against the tissue surface and facilitating imaging fluid retention within hood 282.


Aside from the imaging hood, various instrumentation may be utilized with the imaging and manipulation system. For instance, after the field within imaging hood 12 has been cleared of the opaque blood and the underlying tissue is visualized through the clear fluid, blood may seep back into the imaging hood 12 and obstruct the view. One method for automatically maintaining a clear imaging field may utilize a transducer, e.g., an ultrasonic transducer 290, positioned at the distal end of deployment catheter within the imaging hood 12, as shown in FIG. 23. The transducer 290 may send an energy pulse 292 into the imaging hood 12 and wait to detect back-scattered energy 294 reflected from debris or blood within the imaging hood 12. If back-scattered energy is detected, the pump may be actuated automatically to dispense more fluid into the imaging hood until the debris or blood is no longer detected.


Alternatively, one or more sensors 300 may be positioned on the imaging hood 12 itself, as shown in FIG. 24A, to detect a number of different parameters. For example, sensors 300 may be configured to detect for the presence of oxygen in the surrounding blood, blood and/or imaging fluid pressure, color of the fluid within the imaging hood, etc. Fluid color may be particularly useful in detecting the presence of blood within the imaging hood 12 by utilizing a reflective type sensor to detect back reflection from blood. Any reflected light from blood which may be present within imaging hood 12 may be optically or electrically transmitted through deployment catheter 16 and to a red colored filter within control electronics 118. Any red color which may be detected may indicate the presence of blood and trigger a signal to the physician or automatically actuate the pump to dispense more fluid into the imaging hood 12 to clear the blood.


Alternative methods for detecting the presence of blood within the hood 12 may include detecting transmitted light through the imaging fluid within imaging hood 12. If a source of white light, e.g., utilizing LEDs or optical fibers, is illuminated inside imaging hood 12, the presence of blood may cause the color red to be filtered through this fluid. The degree or intensity of the red color detected may correspond to the amount of blood present within imaging hood 12. A red color sensor can simply comprise, in one variation, a phototransistor with a red transmitting filter over it which can establish how much red light is detected, which in turn can indicate the presence of blood within imaging hood 12. Once blood is detected, the system may pump more clearing fluid through and enable closed loop feedback control of the clearing fluid pressure and flow level.


Any number of sensors may be positioned along the exterior 302 of imaging hood 12 or within the interior 304 of imaging hood 12 to detect parameters not only exteriorly to imaging hood 12 but also within imaging hood 12. Such a configuration, as shown in FIG. 24B, may be particularly useful for automatically maintaining a clear imaging field based upon physical parameters such as blood pressure, as described above for FIGS. 10A and 10B.


Aside from sensors, one or more light emitting diodes (LEDs) may be utilized to provide lighting within the imaging hood 12. Although illumination may be provided by optical fibers routed through deployment catheter 16, the use of LEDs over the imaging hood 12 may eliminate the need for additional optical fibers for providing illumination. The electrical wires connected to the one or more LEDs may be routed through or over the hood 12 and along an exterior surface or extruded within deployment catheter 16. One or more LEDs may be positioned in a circumferential pattern 306 around imaging hood 12, as shown in FIG. 25A, or in a linear longitudinal pattern 308 along imaging hood 12, as shown in FIG. 25B. Other patterns, such as a helical or spiral pattern, may also be utilized. Alternatively, LEDs may be positioned along a support member forming part of imaging hood 12.


In another alternative for illumination within imaging hood 12, a separate illumination tool 310 may be utilized, as shown in FIG. 26A. An example of such a tool may comprise a flexible intravascular delivery member 312 having a carrier member 314 pivotably connected 316 to a distal end of delivery member 312. One or more LEDs 318 may be mounted along carrier member 314. In use, delivery member 312 may be advanced through deployment catheter 16 until carrier member 314 is positioned within imaging hood 12. Once within imaging hood 12, carrier member 314 may be pivoted in any number of directions to facilitate or optimize the illumination within the imaging hood 12, as shown in FIG. 26B.


In utilizing LEDs for illumination, whether positioned along imaging hood 12 or along a separate instrument, the LEDs may comprise a single LED color, e.g., white light. Alternatively, LEDs of other colors, e.g., red, blue, yellow, etc., may be utilized exclusively or in combination with white LEDs to provide for varied illumination of the tissue or fluids being imaged. Alternatively, sources of infrared or ultraviolet light may be employed to enable imaging beneath the tissue surface or cause fluorescence of tissue for use in system guidance, diagnosis, or therapy.


Aside from providing a visualization platform, the imaging assembly may also be utilized to provide a therapeutic platform for treating tissue being visualized. As shown in FIG. 27, deployment catheter 320 may have imaging hood 322, as described above, and fluid delivery lumen 324 and imaging lumen 326. In this variation, a therapeutic tool such as needle 328 may be delivered through fluid delivery lumen 324 or in another working lumen and advanced through open area 332 for treating the tissue which is visualized. In this instance, needle 328 may define one or several ports 330 for delivering drugs therethrough. Thus, once the appropriate region of tissue has been imaged and located, needle 328 may be advanced and pierced into the underlying tissue where a therapeutic agent may be delivered through ports 330. Alternatively, needle 328 may be in electrical communication with power source 334, e.g., radio-frequency, microwave, etc., for ablating the underlying tissue area of interest.



FIG. 28 shows another alternative in which deployment catheter 340 may have imaging hood 342 attached thereto, as above, but with a therapeutic tool 344 in the configuration of a helical tissue piercing device 344. Also shown and described above in FIGS. 7A and 7B for use in stabilizing the imaging hood relative to the underlying tissue, the helical tissue piercing device 344 may also be utilized to manipulate the tissue for a variety of therapeutic procedures. The helical portion 346 may also define one or several ports for delivery of therapeutic agents therethrough.


In yet another alternative, FIG. 29 shows a deployment catheter 350 having an expandable imaging balloon 352 filled with, e.g., saline 356. A therapeutic tool 344, as above, may be translatable relative to balloon 352. To prevent the piercing portion 346 of the tool from tearing balloon 352, a stop 354 may be formed on balloon 352 to prevent the proximal passage of portion 346 past stop 354.


Alternative configurations for tools which may be delivered through deployment catheter 16 for use in tissue manipulation within imaging hood 12 are shown in FIGS. 30A and 30B. FIG. 30A shows one variation of an angled instrument 360, such as a tissue grasper, which may be configured to have an elongate shaft for intravascular delivery through deployment catheter 16 with a distal end which may be angled relative to its elongate shaft upon deployment into imaging hood 12. The elongate shaft may be configured to angle itself automatically, e.g., by the elongate shaft being made at least partially from a shape memory alloy, or upon actuation, e.g., by tensioning a pullwire. FIG. 30B shows another configuration for an instrument 362 being configured to reconfigure its distal portion into an off-axis configuration within imaging hood 12. In either case, the instruments 360, 362 may be reconfigured into a low-profile shape upon withdrawing them proximally back into deployment catheter 16.


Other instruments or tools which may be utilized with the imaging system is shown in the side and end views of FIGS. 31A to 31C. FIG. 31A shows a probe 370 having a distal end effector 372, which may be reconfigured from a low-profile shape to a curved profile. The end effector 372 may be configured as an ablation probe utilizing radio-frequency energy, microwave energy, ultrasound energy, laser energy or even cryo-ablation. Alternatively, the end effector 372 may have several electrodes upon it for detecting or mapping electrical signals transmitted through the underlying tissue.


In the case of an end effector 372 utilized for ablation of the underlying tissue, an additional temperature sensor such as a thermocouple or thermistor 374 positioned upon an elongate member 376 may be advanced into the imaging hood 12 adjacent to the distal end effector 372 for contacting and monitoring a temperature of the ablated tissue. FIG. 31B shows an example in the end view of one configuration for the distal end effector 372 which may be simply angled into a perpendicular configuration for contacting the tissue. FIG. 31C shows another example where the end effector may be reconfigured into a curved end effector 378 for increased tissue contact.



FIGS. 32A and 32B show another variation of an ablation tool utilized with an imaging hood 12 having an enclosed bottom portion. In this variation, an ablation probe, such as a cryo-ablation probe 380 having a distal end effector 382, may be positioned through the imaging hood 12 such that the end effector 382 is placed distally of a transparent membrane or enclosure 384, as shown in the end view of FIG. 32B. The shaft of probe 380 may pass through an opening 386 defined through the membrane 384. In use, the clear fluid may be pumped into imaging hood 12, as described above, and the distal end effector 382 may be placed against a tissue region to be ablated with the imaging hood 12 and the membrane 384 positioned atop or adjacent to the ablated tissue. In the case of cryo-ablation, the imaging fluid may be warmed prior to dispensing into the imaging hood 12 such that the tissue contacted by the membrane 384 may be warmed during the cryo-ablation procedure. In the case of thermal ablation, e.g., utilizing radio-frequency energy, the fluid dispensed into the imaging hood 12 may be cooled such that the tissue contacted by the membrane 384 and adjacent to the ablation probe during the ablation procedure is likewise cooled.


In either example described above, the imaging fluid may be varied in its temperature to facilitate various procedures to be performed upon the tissue. In other cases, the imaging fluid itself may be altered to facilitate various procedures. For instance as shown in FIG. 33A, a deployment catheter 16 and imaging hood 12 may be advanced within a hollow body organ, such as a bladder filled with urine 394, towards a lesion or tumor 392 on the bladder wall. The imaging hood 12 may be placed entirely over the lesion 392, or over a portion of the lesion. Once secured against the tissue wall 390, a cryo-fluid, i.e., a fluid which has been cooled to below freezing temperatures of, e.g., water or blood may be pumped into the imaging hood 12 to cryo-ablate the lesion 390, as shown in FIG. 33B while avoiding the creation of ice on the instrument or surface of tissue.


As the cryo-fluid leaks out of the imaging hood 12 and into the organ, the fluid may be warmed naturally by the patient body and ultimately removed. The cryo-fluid may be a colorless and translucent fluid which enables visualization therethrough of the underlying tissue. An example of such a fluid is Fluorinert™ (3M, St. Paul, Minn.), which is a colorless and odorless perfluorinated liquid. The use of a liquid such as Fluorinert™ enables the cryo-ablation procedure without the formation of ice within or outside of the imaging hood 12. Alternatively, rather than utilizing cryoablation, hyperthermic treatments may also be effected by heating the Fluorinert™ liquid to elevated temperatures for ablating the lesion 392 within the imaging hood 12. Moreover, Fluorinert™ may be utilized in various other parts of the body, such as within the heart.



FIG. 34A shows another variation of an instrument which may be utilized with the imaging system. In this variation, a laser ring generator 400 may be passed through the deployment catheter 16 and partially into imaging hood 12. A laser ring generator 400 is typically used to create a circular ring of laser energy 402 for generating a conduction block around the pulmonary veins typically in the treatment of atrial fibrillation. The circular ring of laser energy 402 may be generated such that a diameter of the ring 402 is contained within a diameter of the imaging hood 12 to allow for tissue ablation directly upon tissue being imaged. Signals which cause atrial fibrillation typically come from the entry area of the pulmonary veins into the left atrium and treatments may sometimes include delivering ablation energy to the ostia of the pulmonary veins within the atrium. The ablated areas of the tissue may produce a circular scar which blocks the impulses for atrial fibrillation.


When using the laser energy to ablate the tissue of the heart, it may be generally desirable to maintain the integrity and health of the tissue overlying the surface while ablating the underlying tissue. This may be accomplished, for example, by cooling the imaging fluid to a temperature below the body temperature of the patient but which is above the freezing point of blood (e.g., 2° C. to 35° C.). The cooled imaging fluid may thus maintain the surface tissue at the cooled fluid temperature while the deeper underlying tissue remains at the patient body temperature. When the laser energy (or other types of energy such as radio frequency energy, microwave energy, ultrasound energy, etc.) irradiates the tissue, both the cooled tissue surface as well as the deeper underlying tissue will rise in temperature uniformly. The deeper underlying tissue, which was maintained at the body temperature, will increase to temperatures which are sufficiently high to destroy the underlying tissue. Meanwhile, the temperature of the cooled surface tissue will also rise but only to temperatures that are near body temperature or slightly above.


Accordingly, as shown in FIG. 34B, one example for treatment may include passing deployment catheter 16 across the atrial septum AS and into the left atrium LA of the patient's heart H. Other methods of accessing the left atrium LA may also be utilized. The imaging hood 12 and laser ring generator 400 may be positioned adjacent to or over one or more of the ostium OT of the pulmonary veins PV and the laser generator 400 may ablate the tissue around the ostium OT with the circular ring of laser energy 402 to create a conduction block. Once one or more of the tissue around the ostium OT have been ablated, the imaging hood 12 may be reconfigured into a low profile for removal from the patient heart H.


One of the difficulties in treating tissue in or around the ostium OT is the dynamic fluid flow of blood through the ostium OT. The dynamic forces make cannulation or entry of the ostium OT difficult. Thus, another variation on instruments or tools utilizable with the imaging system is an extendible cannula 410 having a cannula lumen 412 defined therethrough, as shown in FIG. 35A. The extendible cannula 410 may generally comprise an elongate tubular member which may be positioned within the deployment catheter 16 during delivery and then projected distally through the imaging hood 12 and optionally beyond, as shown in FIG. 35B.


In use, once the imaging hood 12 has been desirably positioned relative to the tissue, e.g., as shown in FIG. 35C outside the ostium OT of a pulmonary vein PV, the extendible cannula 410 may be projected distally from the deployment catheter 16 while optionally imaging the tissue through the imaging hood 12, as described above. The extendible cannula 410 may be projected distally until its distal end is extended at least partially into the ostium OT. Once in the ostium OT, an instrument or energy ablation device may be extended through and out of the cannula lumen 412 for treatment within the ostium OT. Upon completion of the procedure, the cannula 410 may be withdrawn proximally and removed from the patient body. The extendible cannula 410 may also include an inflatable occlusion balloon at or near its distal end to block the blood flow out of the PV to maintain a clear view of the tissue region. Alternatively, the extendible cannula 410 may define a lumen therethrough beyond the occlusion balloon to bypass at least a portion of the blood that normally exits the pulmonary vein PV by directing the blood through the cannula 410 to exit proximal of the imaging hood.


Yet another variation for tool or instrument use may be seen in the side and end views of FIGS. 36A and 36B. In this variation, imaging hood 12 may have one or more tubular support members 420 integrated with the hood 12. Each of the tubular support members 420 may define an access lumen 422 through which one or more instruments or tools may be delivered for treatment upon the underlying tissue. One particular example is shown and described above for FIG. 7C.


Various methods and instruments may be utilized for using or facilitating the use of the system. For instance, one method may include facilitating the initial delivery and placement of a device into the patient's heart. In initially guiding the imaging assembly within the heart chamber to, e.g., the mitral valve MV, a separate guiding probe 430 may be utilized, as shown in FIGS. 37A and 37B. Guiding probe 430 may, for example, comprise an optical fiber through which a light source 434 may be used to illuminate a distal tip portion 432. The tip portion 432 may be advanced into the heart through, e.g., the coronary sinus CS, until the tip is positioned adjacent to the mitral valve MV. The tip 432 may be illuminated, as shown in FIG. 37A, and imaging assembly 10 may then be guided towards the illuminated tip 432, which is visible from within the atrial chamber, towards mitral valve MV.


Aside from the devices and methods described above, the imaging system may be utilized to facilitate various other procedures. Turning now to FIGS. 38A and 38B, the imaging hood of the device in particular may be utilized. In this example, a collapsible membrane or disk-shaped member 440 may be temporarily secured around the contact edge or lip of imaging hood 12. During intravascular delivery, the imaging hood 12 and the attached member 440 may both be in a collapsed configuration to maintain a low profile for delivery. Upon deployment, both the imaging hood 12 and the member 440 may extend into their expanded configurations.


The disk-shaped member 440 may be comprised of a variety of materials depending upon the application. For instance, member 440 may be fabricated from a porous polymeric material infused with a drug eluting medicament 442 for implantation against a tissue surface for slow infusion of the medicament into the underlying tissue. Alternatively, the member 440 may be fabricated from a non-porous material, e.g., metal or polymer, for implantation and closure of a wound or over a cavity to prevent fluid leakage. In yet another alternative, the member 440 may be made from a distensible material which is secured to imaging hood 12 in an expanded condition. Once implanted or secured on a tissue surface or wound, the expanded member 440 may be released from imaging hood 12. Upon release, the expanded member 440 may shrink to a smaller size while approximating the attached underlying tissue, e.g., to close a wound or opening.


One method for securing the disk-shaped member 440 to a tissue surface may include a plurality of tissue anchors 444, e.g., barbs, hooks, projections, etc., which are attached to a surface of the member 440. Other methods of attachments may include adhesives, suturing, etc. In use, as shown in FIGS. 39A to 39C, the imaging hood 12 may be deployed in its expanded configuration with member 440 attached thereto with the plurality of tissue anchors 444 projecting distally. The tissue anchors 444 may be urged into a tissue region to be treated 446, as seen in FIG. 39A, until the anchors 444 are secured in the tissue and member 440 is positioned directly against the tissue, as shown in FIG. 39B. A pullwire may be actuated to release the member 440 from the imaging hood 12 and deployment catheter 16 may be withdrawn proximally to leave member 440 secured against the tissue 446.


Another variation for tissue manipulation and treatment may be seen in the variation of FIG. 40A, which illustrates an imaging hood 12 having a deployable anchor assembly 450 attached to the tissue contact edge 22. FIG. 40B illustrates the anchor assembly 450 detached from the imaging hood 12 for clarity. The anchor assembly 450 may be seen as having a plurality of discrete tissue anchors 456, e.g., barbs, hooks, projections, etc., each having a suture retaining end, e.g., an eyelet or opening 458 in a proximal end of the anchors 456. A suture member or wire 452 may be slidingly connected to each anchor 456 through the openings 458 and through a cinching element 454, which may be configured to slide uni-directionally over the suture or wire 452 to approximate each of the anchors 456 towards one another. Each of the anchors 456 may be temporarily attached to the imaging hood 12 through a variety of methods. For instance, a pullwire or retaining wire may hold each of the anchors within a receiving ring around the circumference of the imaging hood 12. When the anchors 456 are released, the pullwire or retaining wire may be tensioned from its proximal end outside the patient body to thereby free the anchors 456 from the imaging hood 12.


One example for use of the anchor assembly 450 is shown in FIGS. 41A to 41D for closure of an opening or wound 460, e.g., patent foramen ovale (PFO). The deployment catheter 16 and imaging hood 12 may be delivered intravascularly into, e.g., a patient heart. As the imaging hood 12 is deployed into its expanded configuration, the imaging hood 12 may be positioned adjacent to the opening or wound 460, as shown in FIG. 41A. With the anchor assembly 450 positioned upon the expanded imaging hood 12, deployment catheter 16 may be directed to urge the contact edge of imaging hood 12 and anchor assembly 450 into the region surrounding the tissue opening 460, as shown in FIG. 41B. Once the anchor assembly 450 has been secured within the surrounding tissue, the anchors may be released from imaging hood 12 leaving the anchor assembly 450 and suture member 452 trailing from the anchors, as shown in FIG. 41C. The suture or wire member 452 may be tightened by pulling it proximally from outside the patient body to approximate the anchors of anchor assembly 450 towards one another in a purse-string manner to close the tissue opening 462, as shown in FIG. 41D. The cinching element 454 may also be pushed distally over the suture or wire member 452 to prevent the approximated anchor assembly 450 from loosening or widening.


Another example for an alternative use is shown in FIG. 42, where the deployment catheter 16 and deployed imaging hood 12 may be positioned within a patient body for drawing blood 472 into deployment catheter 16. The drawn blood 472 may be pumped through a dialysis unit 470 located externally of the patient body for filtering the drawn blood 472 and the filtered blood may be reintroduced back into the patient.


Yet another variation is shown in FIGS. 43A and 43B, which show a variation of the deployment catheter 480 having a first deployable hood 482 and a second deployable hood 484 positioned distal to the first hood 482. The deployment catheter 480 may also have a side-viewing imaging element 486 positioned between the first and second hoods 482, 484 along the length of the deployment catheter 480. In use, such a device may be introduced through a lumen 488 of a vessel VS, where one or both hoods 482, 484 may be expanded to gently contact the surrounding walls of vessel VS. Once hoods 482, 484 have been expanded, the clear imaging fluid may be pumped in the space defined between the hoods 482, 484 to displace any blood and to create an imaging space 490, as shown in FIG. 43B. With the clear fluid in-between hoods 482, 484, the imaging element 486 may be used to view the surrounding tissue surface contained between hoods 482, 484. Other instruments or tools may be passed through deployment catheter 480 and through one or more openings defined along the catheter 480 for additionally performing therapeutic procedures upon the vessel wall.


Another variation of a deployment catheter 500 which may be used for imaging tissue to the side of the instrument may be seen in FIGS. 44A to 45B. FIGS. 44A and 44B show side and end views of deployment catheter 500 having a side-imaging balloon 502 in an un-inflated low-profile configuration. A side-imaging element 504 may be positioned within a distal portion of the catheter 500 where the balloon 502 is disposed. When balloon 502 is inflated, it may expand radially to contact the surrounding tissue, but where the imaging element 504 is located, a visualization field 506 may be created by the balloon 502, as shown in the side, top, and end views of FIGS. 45A to 45B, respectively. The visualization field 506 may simply be a cavity or channel which is defined within the inflated balloon 502 such that the visualization element 504 is provided an image of the area within field 506 which is clear and unobstructed by balloon 502.


In use, deployment catheter 500 may be advanced intravascularly through vessel lumen 488 towards a lesion or tumor 508 to be visualized and/or treated. Upon reaching the lesion 508, deployment catheter 500 may be positioned adjacently to the lesion 508 and balloon 502 may be inflated such that the lesion 508 is contained within the visualization field 506. Once balloon 502 is fully inflated and in contact against the vessel wall, clear fluid may be pumped into visualization field 506 through deployment catheter 500 to displace any blood or opaque fluids from the field 506, as shown in the side and end views of FIGS. 46A and 46B, respectively. The lesion 508 may then be visually inspected and treated by passing any number of instruments through deployment catheter 500 and into field 506.


As shown and described above, in placing the hood against a region of tissue to be imaged and/or treated, various configurations of the hood may be utilized to ensure sufficient temporary contact or seal creation between the hood and the underlying tissue for injecting the displacing fluid into the hood. Such contact may be particularly desirable when attempting to locate certain anatomical features utilizing direct visualization. For instance, in locating and visualizing the ostium of the coronary sinus of a patient's heart, images of the surrounding tissue at several different locations within the heart chamber may be needed before locating the ostium. Thus, the ability to rapidly and accurately visualize the underlying tissue is desirable.


Accordingly, additional variations for effectively facilitating the sufficient formation of the temporary seal are further described. An example is illustrated in the side views of FIGS. 47A to 47C, which show hood 12 having an inflatable circumferential balloon which may protrude distally from the hood 12 to provide a wider viewing angle of the underlying contacted tissue.



FIG. 47A shows hood 12, having a number of longitudinally aligned structural supports 510 extending along the hood 12. Imaging element 512, e.g., a CCD or CMOS imager or optical fiber, positioned along an inner surface 516 of hood 12 may be used to provide direct visualization of the open area 26 within hood 12. Circumferential balloon 514 may be positioned along the inner surface 516 of hood 12 in its deflated state during intravascular delivery and when hood 12 is collapsed in its low profile. When deflated, balloon 514 may be lie flat against inner surface 516 such that open area 26 is unobstructed. During inflation, balloon 514 may be infused with a clear fluid, such as saline, or a gas, such as carbon dioxide or air, such that as balloon 514 expands circumferentially, a central lumen 518 is formed by the balloon 514 within open area 26 of hood 12, as shown in FIG. 47B. Moreover, as the balloon 514 expands, it may extend distally past the atraumatic contact lip or edge 22 of hood 12, as shown in FIG. 47B. Once balloon 514 is fully expanded, the lumen 518 may be closed entirely and balloon 514 may occupy the entire volume of hood 12. The portion of balloon 514 which is inflated and extended beyond lip 22 may create an expanded range of view through which the imager 512 may visualize through.



FIG. 48 shows an example of how the field of view 522 from imaging element 512, which may be articulated as illustrated by the direction of rotation 520, through the distally expanded balloon 514 may be increased for imaging the tissue beyond contact lip 22. FIG. 49 illustrates the fully inflated balloon 514 pressed against the tissue surface T where the contact lip 22 is raised away from the tissue surface by balloon 514 to provide the expanded field of view through the balloon. In use, balloon 514 may be expanded within hood 12 to provide an initial visual assessment of the location of hood 12 along the tissue surface as imager 512 may view the contacted underlying tissue through the balloon 514. Once a suitable location has been found, balloon 514 may be deflated such that it collapses back into its low profile shape against the inner surface 516 of hood 12, which may then be infused with the clear fluid for displacing any blood trapped within hood 12 for directly visualizing and treating the tissue unobstructed by balloon 514.


Additional details on various configurations and methods of use for a hood 12 utilizing an expanded balloon therewithin are shown and described in further detail in U.S. patent application Ser. No. 11/775,771 filed Jul. 10, 2007, which is incorporated herein by reference in its entirety.


As previously mentioned, the visualization and treatment assemblies may be utilized to locate anatomical features such as the ostium OT of the coronary sinus CS, for instance, for passing a guidewire into the coronary sinus CS. Turning now to FIGS. 50A to 50E, an example is illustrated showing cannulation of the coronary sinus CS. FIG. 50A shows deployment catheter 16 introduced intravascularly into, e.g., the right atrium RA via entry through the superior vena cava SVC. Although entry is shown via the superior vena cava SVC, other pathways may also be utilized, such as through the inferior vena cava. In either case, once deployment catheter 16 has been introduced into the right atrium RA, the distal portion 530 of catheter 16 may be configured to articulate, as described above, into various configurations to facilitate positioning of the catheter 16 within the heart chamber.


As shown in FIG. 50B, with catheter 16 initially positioned within the right atrium RA, hood 12 flay be deployed into its expanded configuration and placed into contact against the tissue surface, as indicated by arrows 532, at an initial location flood 12 may be infused with the transparent or translucent fluid and the underlying tissue may be visualized through the fluid via imaging element 512, as described above, to provide an initial visual image of the tissue region to the user. The appearance of the visualized tissue may provide an indication to the user of the location of the hood 12 along the tissue surface, e.g., based upon color differences in the tissue or surface appearance of the tissue. Additionally and/or optionally, balloon 514 may be expanded within hood 12 and into contact against the underlying tissue and the contacted tissue region may be visualized through the balloon 514 rather than flushing the open area of the hood 12 with the transparent fluid. Making an initial visual determination of the tissue through the balloon 514 may facilitate the procedure.


When an initial visual determination has been made, hood 12 may be disengaged or removed from the tissue surface and moved to another location along the heart chamber, where hood 12 may be brought again into contact and re-purged with the transparent fluid for visualizing the second location. Alternatively, if balloon 514 is utilized for visualizing the tissue, hood 12 may be articulated to move or slide balloon 514 along the tissue surface while maintaining contact between the tissue and balloon 514, as indicated by the direction of arrow 534 in FIG. 50C. Maintaining contact between balloon 514 and the tissue surface may enable continued visualization through hood 12 via balloon 514 of the tissue surface and may also provide an indication to the user as to the direction in which to articulate hood 12.


With the use of hood 12 alone or optionally with balloon 514, hood 12 may be further articulated in a direction 536, as shown in FIG. 50D, until it is positioned over or upon the ostium OT of the coronary sinus CS. The positioning of hood 12 over or upon the ostium OT may be visually confirmed by an influx of blood into hood 12 when viewed directly through the transparent fluid within hood 12 or by the presence of a red portion contrasted against the color of the tissue surface surrounding the ostium OT when viewed through inflated balloon 514. The red portion may represent the outflow of blood from the coronary sinus CS to the right atrium RA that is temporarily blocked by balloon 514 that is in contact with the ostium OT.


Once the location the ostium OT of the coronary sinus CS has been located, a guidewire 538 or other instrument may be passed through deployment catheter 16 and into hood 12, either through central lumen 518 of a partially deflated balloon 514 or directly through the transparent fluid, while under direct visual guidance from imaging element 512. Guidewire 538 can be conveniently inserted into the coronary sinus CS so long as a portion of the coronary sinus ostium OT is encompassed and identified within the hood 12. FIG. 50E illustrates hood 12 and balloon 514 positioned over the coronary sinus ostium OT while advancing guidewire 538 further into the coronary sinus CS.


Variations of the tissue visualization catheter and their methods of use may provide a platform that allow users a direct method to locate and/or cannulate a morphological feature, such as the coronary sinus CS, within a heart chamber filled with opaque blood with the ability to perform a variety of therapeutic tissue treatments under direct in vivo visualization. Accordingly, a guidewire 538 can be delivered directly into the coronary sinus CS upon identifying its location while utilizing the same device and under direct visualization to obviate having to reposition the entire device and/or repeat an entire sequence of operations, consequently improving procedure effectiveness and reducing procedure time.


The applications of the disclosed invention discussed above are not limited to certain treatments or regions of the body, but may include any number of other treatments and areas of the body. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the arts are intended to be within the scope of this disclosure. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure as well.

Claims
  • 1. A method of cannulating a coronary sinus within a heart chamber, comprising: deploying, from a catheter, an imaging hood to a deployed configuration by extending the imaging hood from a distal end of the catheter and radially expanding the imaging hood to define a deployed volume within an open area of the imaging hood, wherein the deployed volume is constant;positioning a contact edge of the imaging hood and the open area of the imaging hood in the deployed configuration over or upon an ostium of the coronary sinus;displacing an opaque fluid with a transparent fluid from the open area defined by the imaging hood and tissue surrounding the ostium;visualizing the ostium through the transparent fluid by viewing the ostium via an imaging element attached to an inner surface of the imaging hood; andintroducing a guidewire through the imaging hood and into the ostium while under visual guidance.
  • 2. The method of claim 1 wherein positioning further comprises advancing the imaging hood into a left atrial chamber of a heart.
  • 3. The method of claim 1 wherein displacing the opaque fluid comprises infusing the transparent fluid into the open area through a fluid delivery lumen defined through the catheter through which the imaging hood extends.
  • 4. The method of claim 3 wherein infusing the transparent fluid comprises pumping saline, plasma, water, or perfluorinated liquid into the open area such that blood is displaced therefrom.
  • 5. The method of claim 1 wherein the imaging element comprises a CMOS imager, CCD imager, or optical fiber.
  • 6. The method of claim 1 wherein introducing the guidewire comprises passing the guidewire through the catheter and into the imaging hood for advancement into the ostium.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 11/848,207, filed Aug. 30, 2007, which claims the benefit of priority to U.S. Prov. Pat. App. 60/824,423, filed Sep. 1, 2006, both disclosures of which are incorporated herein by reference in their entireties.

US Referenced Citations (652)
Number Name Date Kind
623022 Johnson Apr 1899 A
2305462 Wolf Dec 1942 A
2453862 Salisbury Nov 1948 A
3559651 David Feb 1971 A
3831587 Boyd Aug 1974 A
3874388 King et al. Apr 1975 A
3903877 Terada Sep 1975 A
4175545 Termanini Nov 1979 A
4198981 Sinnreich Apr 1980 A
4326529 Doss et al. Apr 1982 A
4403612 Fogarty Sep 1983 A
4445892 Hussein et al. May 1984 A
4470407 Hussein Sep 1984 A
4517976 Murakoshi et al. May 1985 A
4569335 Tsuno Feb 1986 A
4576146 Kawazoe et al. Mar 1986 A
4615333 Taguchi Oct 1986 A
4619247 Inoue et al. Oct 1986 A
4676258 Inokuchi et al. Jun 1987 A
4681093 Ono et al. Jul 1987 A
4696668 Wilcox Sep 1987 A
4709698 Johnston et al. Dec 1987 A
4710192 Liotta et al. Dec 1987 A
4727418 Kato et al. Feb 1988 A
4772260 Heyden Sep 1988 A
4784133 Mackin Nov 1988 A
4838246 Hahn et al. Jun 1989 A
4848323 Marijnissen et al. Jul 1989 A
4880015 Nierman Nov 1989 A
4911148 Sosnowski et al. Mar 1990 A
4914521 Adair Apr 1990 A
4943290 Rexroth et al. Jul 1990 A
4950285 Wilk Aug 1990 A
4957484 Murtfeldt Sep 1990 A
4960411 Buchbinder Oct 1990 A
4961738 Mackin Oct 1990 A
4976710 Mackin Dec 1990 A
4991578 Cohen Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
4998916 Hammerslag et al. Mar 1991 A
4998972 Chin et al. Mar 1991 A
5025778 Silverstein et al. Jun 1991 A
5047028 Qian Sep 1991 A
5057106 Kasevich et al. Oct 1991 A
5090959 Samson et al. Feb 1992 A
5123428 Schwarz Jun 1992 A
RE34002 Adair Jul 1992 E
5156141 Krebs et al. Oct 1992 A
5171259 Inoue Dec 1992 A
5197457 Adair Mar 1993 A
5281238 Chin et al. Jan 1994 A
5282827 Kensey et al. Feb 1994 A
5306234 Johnson Apr 1994 A
5313934 Wiita et al. May 1994 A
5313943 Houser et al. May 1994 A
5330496 Alferness Jul 1994 A
5334159 Turkel Aug 1994 A
5334193 Nardella Aug 1994 A
5336252 Cohen Aug 1994 A
5339800 Wiita et al. Aug 1994 A
5345927 Bonutti Sep 1994 A
5348554 Imran et al. Sep 1994 A
5353792 Luebbers et al. Oct 1994 A
5370647 Graber et al. Dec 1994 A
5373840 Knighton Dec 1994 A
5375612 Cottenceau et al. Dec 1994 A
5385146 Goldreyer Jan 1995 A
5385148 Lesh et al. Jan 1995 A
5391182 Chin Feb 1995 A
5391199 Ben-Haim Feb 1995 A
5403311 Abele et al. Apr 1995 A
5403326 Harrison et al. Apr 1995 A
5405360 Tovey Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5411016 Kume et al. May 1995 A
5413104 Buijs et al. May 1995 A
5421338 Crowley et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5453785 Lenhardt et al. Sep 1995 A
5458612 Chin Oct 1995 A
5462521 Brucker et al. Oct 1995 A
5471515 Fossum et al. Nov 1995 A
5498230 Adair Mar 1996 A
5505730 Edwards Apr 1996 A
5515853 Smith et al. May 1996 A
5527338 Purdy Jun 1996 A
5549603 Feiring Aug 1996 A
5558619 Kami et al. Sep 1996 A
5571088 Lennox et al. Nov 1996 A
5575756 Karasawa et al. Nov 1996 A
5575810 Swanson et al. Nov 1996 A
5584872 Lafontaine et al. Dec 1996 A
5591119 Adair Jan 1997 A
5593405 Osypka Jan 1997 A
5593422 Muijs et al. Jan 1997 A
5593424 Northrup III Jan 1997 A
5643282 Kieturakis Jul 1997 A
5653677 Okada et al. Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5665062 Houser Sep 1997 A
5672153 Lax et al. Sep 1997 A
5676693 Lafontaine Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5695448 Kimura et al. Dec 1997 A
5697281 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5709224 Behl et al. Jan 1998 A
5713907 Hogendijk et al. Feb 1998 A
5713946 Ben-Haim Feb 1998 A
5716321 Kerin et al. Feb 1998 A
5716325 Bonutti Feb 1998 A
5722403 McGee et al. Mar 1998 A
5725523 Mueller Mar 1998 A
5743851 Moll et al. Apr 1998 A
5746747 McKeating May 1998 A
5749846 Edwards et al. May 1998 A
5749889 Bacich et al. May 1998 A
5749890 Shaknovich May 1998 A
5754313 Pelchy et al. May 1998 A
5766137 Omata Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5792045 Adair Aug 1998 A
5797903 Swanson et al. Aug 1998 A
5823947 Yoon et al. Oct 1998 A
5827175 Tanaka et al. Oct 1998 A
5827268 Laufer Oct 1998 A
5829447 Stevens et al. Nov 1998 A
5842973 Bullard Dec 1998 A
5843118 Sepetka et al. Dec 1998 A
5846221 Snoke et al. Dec 1998 A
5846239 Swanson et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5860974 Abele Jan 1999 A
5860991 Klein et al. Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5873815 Kerin et al. Feb 1999 A
5879366 Shaw et al. Mar 1999 A
5895417 Pomeranz et al. Apr 1999 A
5897487 Ouchi Apr 1999 A
5897553 Mulier et al. Apr 1999 A
5902328 Lafontaine et al. May 1999 A
5904651 Swanson et al. May 1999 A
5908445 Whayne et al. Jun 1999 A
5916147 Boury Jun 1999 A
5925038 Panescu et al. Jul 1999 A
5928250 Koike et al. Jul 1999 A
5929901 Adair et al. Jul 1999 A
5937614 Watkins et al. Aug 1999 A
5941845 Tu et al. Aug 1999 A
5944690 Falwell et al. Aug 1999 A
5964755 Edwards Oct 1999 A
5968053 Revelas Oct 1999 A
5971983 Lesh Oct 1999 A
5980484 Ressemann et al. Nov 1999 A
5985307 Hanson et al. Nov 1999 A
5986693 Adair et al. Nov 1999 A
5997571 Farr et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6007521 Bidwell et al. Dec 1999 A
6012457 Lesh Jan 2000 A
6013024 Mitsuda et al. Jan 2000 A
6024740 Lesh et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6036685 Mueller Mar 2000 A
6043839 Adair et al. Mar 2000 A
6047218 Whayne Apr 2000 A
6063077 Schaer May 2000 A
6063081 Mulier et al. May 2000 A
6068653 Lafontaine May 2000 A
6071279 Whayne et al. Jun 2000 A
6071302 Sinofsky et al. Jun 2000 A
6081740 Gombrich et al. Jun 2000 A
6086528 Adair Jul 2000 A
6086534 Kesten Jul 2000 A
6099498 Addis Aug 2000 A
6099514 Sharkey et al. Aug 2000 A
6102905 Baxter et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6115626 Whayne et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6123718 Tu et al. Sep 2000 A
6129724 Fleischman et al. Oct 2000 A
6139508 Simpson et al. Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6156350 Constantz Dec 2000 A
6159203 Sinofsky Dec 2000 A
6161543 Cox et al. Dec 2000 A
6164283 Lesh Dec 2000 A
6167297 Benaron Dec 2000 A
6168591 Sinofsky Jan 2001 B1
6168594 Lafontaine et al. Jan 2001 B1
6174307 Daniel et al. Jan 2001 B1
6178346 Amundson et al. Jan 2001 B1
6190381 Olsen et al. Feb 2001 B1
6211904 Adair et al. Apr 2001 B1
6224553 Nevo May 2001 B1
6231561 Frazier et al. May 2001 B1
6234995 Peacock, III May 2001 B1
6235044 Root et al. May 2001 B1
6237605 Vaska et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6240312 Alfano et al. May 2001 B1
6254598 Edwards et al. Jul 2001 B1
6258083 Daniel et al. Jul 2001 B1
6263224 West Jul 2001 B1
6266551 Osadchy et al. Jul 2001 B1
6270492 Sinofsky Aug 2001 B1
6275255 Adair et al. Aug 2001 B1
6280450 McGuckin, Jr. Aug 2001 B1
6290689 Delaney et al. Sep 2001 B1
6306081 Ishikawa et al. Oct 2001 B1
6310642 Adair et al. Oct 2001 B1
6311692 Vaska et al. Nov 2001 B1
6314962 Vaska et al. Nov 2001 B1
6314963 Vaska et al. Nov 2001 B1
6315777 Comben Nov 2001 B1
6315778 Gambale et al. Nov 2001 B1
6322536 Rosengart et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6328727 Frazier et al. Dec 2001 B1
6358247 Altman et al. Mar 2002 B1
6358248 Mulier et al. Mar 2002 B1
6375654 McIntyre Apr 2002 B1
6379345 Constantz Apr 2002 B1
6383195 Richard May 2002 B1
6385476 Osadchy et al. May 2002 B1
6387043 Yoon May 2002 B1
6387071 Constantz May 2002 B1
6394096 Constantz May 2002 B1
6396873 Goldstein et al. May 2002 B1
6398780 Farley et al. Jun 2002 B1
6401719 Farley et al. Jun 2002 B1
6409722 Hoey et al. Jun 2002 B1
6416511 Lesh et al. Jul 2002 B1
6419669 Frazier et al. Jul 2002 B1
6423051 Kaplan et al. Jul 2002 B1
6423055 Farr et al. Jul 2002 B1
6423058 Edwards et al. Jul 2002 B1
6428536 Panescu et al. Aug 2002 B2
6436118 Kayan Aug 2002 B1
6440061 Wenner et al. Aug 2002 B1
6440119 Nakada et al. Aug 2002 B1
6458151 Saltiel Oct 2002 B1
6461327 Addis et al. Oct 2002 B1
6464697 Edwards et al. Oct 2002 B1
6474340 Vaska et al. Nov 2002 B1
6475223 Werp et al. Nov 2002 B1
6478769 Parker Nov 2002 B1
6482162 Moore Nov 2002 B1
6484727 Vaska et al. Nov 2002 B1
6485489 Teirstein et al. Nov 2002 B2
6488671 Constantz et al. Dec 2002 B1
6494902 Hoey et al. Dec 2002 B2
6497651 Kan et al. Dec 2002 B1
6497705 Comben Dec 2002 B2
6500174 Maguire et al. Dec 2002 B1
6502576 Lesh Jan 2003 B1
6514249 Maguire et al. Feb 2003 B1
6517533 Swaminathan Feb 2003 B1
6527979 Constantz et al. Mar 2003 B2
6532380 Close et al. Mar 2003 B1
6533767 Johansson et al. Mar 2003 B2
6537272 Christopherson et al. Mar 2003 B2
6540733 Constantz et al. Apr 2003 B2
6540744 Hassett et al. Apr 2003 B2
6544195 Wilson et al. Apr 2003 B2
6547780 Sinofsky Apr 2003 B1
6549800 Atalar et al. Apr 2003 B1
6558375 Sinofsky et al. May 2003 B1
6558382 Jahns et al. May 2003 B2
6562020 Constantz et al. May 2003 B1
6572609 Farr et al. Jun 2003 B1
6579285 Sinofsky Jun 2003 B2
6585732 Mulier et al. Jul 2003 B2
6587709 Solf et al. Jul 2003 B2
6593884 Gilboa et al. Jul 2003 B1
6605055 Sinofsky et al. Aug 2003 B1
6613062 Leckrone et al. Sep 2003 B1
6622732 Constantz Sep 2003 B2
6626855 Weng et al. Sep 2003 B1
6626899 Houser et al. Sep 2003 B2
6626900 Sinofsky et al. Sep 2003 B1
6632171 Iddan et al. Oct 2003 B2
6635070 Leeflang et al. Oct 2003 B2
6645202 Pless et al. Nov 2003 B1
6650923 Lesh et al. Nov 2003 B1
6658279 Swanson et al. Dec 2003 B2
6659940 Adler Dec 2003 B2
6663821 Seward Dec 2003 B2
6673090 Root et al. Jan 2004 B2
6676656 Sinofsky Jan 2004 B2
6679836 Couvillon, Jr. et al. Jan 2004 B2
6682526 Jones et al. Jan 2004 B1
6689051 Nakada et al. Feb 2004 B2
6689128 Sliwa et al. Feb 2004 B2
6692430 Adler Feb 2004 B2
6701581 Senovich et al. Mar 2004 B2
6701931 Sliwa et al. Mar 2004 B2
6702780 Gilboa et al. Mar 2004 B1
6704043 Goldstein et al. Mar 2004 B2
6706039 Mulier et al. Mar 2004 B2
6712798 Constantz Mar 2004 B2
6719747 Constantz et al. Apr 2004 B2
6719755 Sliwa et al. Apr 2004 B2
6730063 Delaney et al. May 2004 B2
6736810 Hoey et al. May 2004 B2
6749617 Palasis et al. Jun 2004 B1
6751492 Ben-Haim Jun 2004 B2
6755790 Stewart et al. Jun 2004 B2
6755811 Constantz Jun 2004 B1
6764487 Mulier et al. Jul 2004 B2
6770070 Balbierz Aug 2004 B1
6771996 Bowe et al. Aug 2004 B2
6773402 Govari et al. Aug 2004 B2
6780151 Grabover et al. Aug 2004 B2
6805128 Pless et al. Oct 2004 B1
6805129 Pless et al. Oct 2004 B1
6811562 Pless Nov 2004 B1
6833814 Gilboa et al. Dec 2004 B2
6840923 Lapcevic Jan 2005 B1
6840936 Sliwa et al. Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6858005 Ohline et al. Feb 2005 B2
6858026 Sliwa et al. Feb 2005 B2
6858905 Hsu Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6866651 Constantz Mar 2005 B2
6887237 McGaffigan May 2005 B2
6892091 Ben-Haim et al. May 2005 B1
6896690 Lambrecht et al. May 2005 B1
6899672 Chin et al. May 2005 B2
6915154 Docherty et al. Jul 2005 B1
6916284 Moriyama Jul 2005 B2
6916286 Kazakevich Jul 2005 B2
6923805 Lafontaine et al. Aug 2005 B1
6929010 Vaska et al. Aug 2005 B2
6932809 Sinofsky Aug 2005 B2
6939348 Malecki et al. Sep 2005 B2
6942657 Sinofsky et al. Sep 2005 B2
6949095 Vaska et al. Sep 2005 B2
6953457 Farr et al. Oct 2005 B2
6955173 Lesh Oct 2005 B2
6958069 Shipp et al. Oct 2005 B2
6962589 Mulier et al. Nov 2005 B2
6971394 Sliwa et al. Dec 2005 B2
6974464 Quijano et al. Dec 2005 B2
6979290 Mourlas et al. Dec 2005 B2
6982740 Adair et al. Jan 2006 B2
6984232 Vanney et al. Jan 2006 B2
6994094 Schwartz Feb 2006 B2
7001329 Kobayashi et al. Feb 2006 B2
7019610 Creighton et al. Mar 2006 B2
7025746 Tal Apr 2006 B2
7030904 Adair et al. Apr 2006 B2
7041098 Farley et al. May 2006 B2
7042487 Nakashima May 2006 B2
7044135 Lesh May 2006 B2
7052493 Vaska et al. May 2006 B2
7090683 Brock et al. Aug 2006 B2
7118566 Jahns Oct 2006 B2
7156845 Mulier et al. Jan 2007 B2
7163534 Brucker et al. Jan 2007 B2
7166537 Jacobsen et al. Jan 2007 B2
7169144 Hoey et al. Jan 2007 B2
7179224 Willis Feb 2007 B2
7186214 Ness Mar 2007 B2
7207984 Farr et al. Apr 2007 B2
7217268 Eggers et al. May 2007 B2
7242832 Carlin et al. Jul 2007 B2
7247155 Hoey et al. Jul 2007 B2
7261711 Mulier et al. Aug 2007 B2
7263397 Hauck et al. Aug 2007 B2
7276061 Schaer et al. Oct 2007 B2
7309328 Kaplan et al. Dec 2007 B2
7322934 Miyake et al. Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7416552 Paul et al. Aug 2008 B2
7435248 Taimisto et al. Oct 2008 B2
7527625 Knight et al. May 2009 B2
7534204 Starksen et al. May 2009 B2
7534294 Gaynor et al. May 2009 B1
7569052 Phan et al. Aug 2009 B2
7569952 Bono et al. Aug 2009 B1
7736347 Kaplan et al. Jun 2010 B2
7758499 Adler Jul 2010 B2
7860555 Saadat Dec 2010 B2
7860556 Saadat Dec 2010 B2
7918787 Saadat Apr 2011 B2
7919610 Serebriiskii et al. Apr 2011 B2
7930016 Saadat Apr 2011 B1
8050746 Saadat et al. Nov 2011 B2
8078266 Saadat et al. Dec 2011 B2
8131350 Saadat et al. Mar 2012 B2
8137333 Saadat et al. Mar 2012 B2
8221310 Saadat et al. Jul 2012 B2
8235985 Saadat et al. Aug 2012 B2
8333012 Rothe et al. Dec 2012 B2
8417321 Saadat et al. Apr 2013 B2
8419613 Saadat et al. Apr 2013 B2
8475361 Barlow et al. Jul 2013 B2
8657805 Peh et al. Feb 2014 B2
8758229 Saadat et al. Jun 2014 B2
8814845 Saadat et al. Aug 2014 B2
8906007 Bonn et al. Dec 2014 B2
8934962 Saadat et al. Jan 2015 B2
9055906 Saadat et al. Jun 2015 B2
9155587 Willis et al. Oct 2015 B2
9192287 Saadat et al. Nov 2015 B2
9226648 Saadat et al. Jan 2016 B2
9332893 Saadat et al. May 2016 B2
9510732 Miller et al. Dec 2016 B2
9526401 Saadat et al. Dec 2016 B2
10004388 Saadat et al. Jun 2018 B2
10064540 Saadat et al. Sep 2018 B2
10070772 Peh et al. Sep 2018 B2
10092172 Peh et al. Oct 2018 B2
10278588 Saadat et al. May 2019 B2
10368729 Miller et al. Aug 2019 B2
10390685 Saadat et al. Aug 2019 B2
10463237 Saadat et al. Nov 2019 B2
10470643 Saadat et al. Nov 2019 B2
10772492 Miller et al. Sep 2020 B2
20010020126 Swanson Sep 2001 A1
20010039416 Moorman et al. Nov 2001 A1
20010047136 Domanik et al. Nov 2001 A1
20010047184 Connors Nov 2001 A1
20020004644 Koblish Jan 2002 A1
20020026145 Bagaoisan et al. Feb 2002 A1
20020035311 Ouchi Mar 2002 A1
20020054852 Cate May 2002 A1
20020065455 Ben-Haim et al. May 2002 A1
20020077594 Chien et al. Jun 2002 A1
20020077642 Patel et al. Jun 2002 A1
20020087169 Brock et al. Jul 2002 A1
20020091304 Ogura et al. Jul 2002 A1
20020138088 Nash et al. Sep 2002 A1
20020161377 Rabkin et al. Oct 2002 A1
20020165598 Wahr et al. Nov 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20030009085 Arai et al. Jan 2003 A1
20030014010 Carpenter et al. Jan 2003 A1
20030018358 Saadat Jan 2003 A1
20030035156 Cooper Feb 2003 A1
20030036698 Kohler et al. Feb 2003 A1
20030065267 Smith Apr 2003 A1
20030069593 Tremulis et al. Apr 2003 A1
20030120142 Dubuc et al. Jun 2003 A1
20030130572 Phan et al. Jul 2003 A1
20030144657 Bowe et al. Jul 2003 A1
20030171741 Ziebol et al. Sep 2003 A1
20030181939 Bonutti Sep 2003 A1
20030208222 Zadno-Azizi Nov 2003 A1
20030212394 Pearson et al. Nov 2003 A1
20030220574 Markus et al. Nov 2003 A1
20030222325 Jacobsen et al. Dec 2003 A1
20030236493 Mauch Dec 2003 A1
20040044350 Martin et al. Mar 2004 A1
20040049211 Tremulis et al. Mar 2004 A1
20040054335 Lesh et al. Mar 2004 A1
20040054389 Osypka Mar 2004 A1
20040082833 Adler et al. Apr 2004 A1
20040097792 Moll et al. May 2004 A1
20040097805 Verard et al. May 2004 A1
20040098031 Van et al. May 2004 A1
20040117032 Roth Jun 2004 A1
20040133113 Krishnan Jul 2004 A1
20040138529 Wiltshire Jul 2004 A1
20040138707 Greenhalgh Jul 2004 A1
20040147806 Adler Jul 2004 A1
20040147911 Sinofsky Jul 2004 A1
20040147912 Sinofsky Jul 2004 A1
20040147913 Sinofsky Jul 2004 A1
20040158143 Flaherty et al. Aug 2004 A1
20040158289 Girouard et al. Aug 2004 A1
20040165766 Goto Aug 2004 A1
20040167503 Sinofsky Aug 2004 A1
20040181237 Forde et al. Sep 2004 A1
20040199052 Banik et al. Oct 2004 A1
20040210111 Okada Oct 2004 A1
20040210239 Nash et al. Oct 2004 A1
20040210278 Boll et al. Oct 2004 A1
20040215180 Starkebaum et al. Oct 2004 A1
20040220471 Schwartz Nov 2004 A1
20040230131 Kassab et al. Nov 2004 A1
20040248837 Raz et al. Dec 2004 A1
20040249367 Saadat et al. Dec 2004 A1
20040254523 Fitzgerald et al. Dec 2004 A1
20040260182 Zuluaga et al. Dec 2004 A1
20040267084 Navia Dec 2004 A1
20050004597 McGuckin et al. Jan 2005 A1
20050014995 Amundson et al. Jan 2005 A1
20050015048 Chiu et al. Jan 2005 A1
20050020914 Amundson et al. Jan 2005 A1
20050027163 Chin et al. Feb 2005 A1
20050038419 Arnold et al. Feb 2005 A9
20050059862 Phan Mar 2005 A1
20050059954 Constantz Mar 2005 A1
20050059965 Eberl et al. Mar 2005 A1
20050059984 Chanduszko et al. Mar 2005 A1
20050065504 Melsky et al. Mar 2005 A1
20050090818 Pike, Jr. et al. Apr 2005 A1
20050096502 Khalili May 2005 A1
20050096643 Brucker et al. May 2005 A1
20050101984 Chanduszko et al. May 2005 A1
20050107736 Landman et al. May 2005 A1
20050124969 Fitzgerald et al. Jun 2005 A1
20050131401 Malecki et al. Jun 2005 A1
20050154252 Sharkey et al. Jul 2005 A1
20050159702 Sekiguchi et al. Jul 2005 A1
20050165272 Okada et al. Jul 2005 A1
20050165279 Adler et al. Jul 2005 A1
20050165391 Maguire et al. Jul 2005 A1
20050165466 Morris et al. Jul 2005 A1
20050197530 Wallace et al. Sep 2005 A1
20050197623 Leeflang et al. Sep 2005 A1
20050215895 Popp et al. Sep 2005 A1
20050222554 Wallace et al. Oct 2005 A1
20050222557 Baxter et al. Oct 2005 A1
20050222558 Baxter et al. Oct 2005 A1
20050228452 Mourlas et al. Oct 2005 A1
20050234436 Baxter et al. Oct 2005 A1
20050234437 Baxter et al. Oct 2005 A1
20050267328 Blumzvig et al. Dec 2005 A1
20050288632 Willard Dec 2005 A1
20060009715 Khairkhahan et al. Jan 2006 A1
20060009737 Whiting et al. Jan 2006 A1
20060015096 Hauck et al. Jan 2006 A1
20060022234 Adair et al. Feb 2006 A1
20060025651 Adler et al. Feb 2006 A1
20060025787 Morales et al. Feb 2006 A1
20060058598 Esposito Mar 2006 A1
20060069303 Couvillon, Jr. Mar 2006 A1
20060074398 Whiting et al. Apr 2006 A1
20060084839 Mourlas et al. Apr 2006 A1
20060084945 Moll et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060111614 Saadat et al. May 2006 A1
20060111692 Hlavka et al. May 2006 A1
20060122587 Sharareh Jun 2006 A1
20060146172 Jacobsen et al. Jul 2006 A1
20060149129 Watts et al. Jul 2006 A1
20060149331 Mann et al. Jul 2006 A1
20060155242 Constantz Jul 2006 A1
20060161133 Laird et al. Jul 2006 A1
20060167439 Kalser et al. Jul 2006 A1
20060183992 Kawashima Aug 2006 A1
20060195060 Navia et al. Aug 2006 A1
20060217755 Eversull et al. Sep 2006 A1
20060224167 Weisenburgh, II et al. Oct 2006 A1
20060253113 Arnold et al. Nov 2006 A1
20060258909 Saadat et al. Nov 2006 A1
20060271032 Chin et al. Nov 2006 A1
20070005019 Okishige Jan 2007 A1
20070015964 Eversull et al. Jan 2007 A1
20070016130 Leeflang et al. Jan 2007 A1
20070043338 Moll et al. Feb 2007 A1
20070043413 Eversull et al. Feb 2007 A1
20070049923 Jahns Mar 2007 A1
20070055142 Webler Mar 2007 A1
20070078451 Arnold et al. Apr 2007 A1
20070083099 Henderson Apr 2007 A1
20070083187 Eversull et al. Apr 2007 A1
20070083217 Eversull et al. Apr 2007 A1
20070093808 Mulier et al. Apr 2007 A1
20070100324 Tempel et al. May 2007 A1
20070106146 Altmann et al. May 2007 A1
20070106214 Gray et al. May 2007 A1
20070106287 O'Sullivan May 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070167801 Webler et al. Jul 2007 A1
20070239010 Johnson Oct 2007 A1
20070265609 Thapliyal et al. Nov 2007 A1
20070265610 Thapliyal et al. Nov 2007 A1
20070270639 Long Nov 2007 A1
20070270686 Ritter et al. Nov 2007 A1
20070282371 Lee et al. Dec 2007 A1
20070293724 Saadat et al. Dec 2007 A1
20080009747 Saadat et al. Jan 2008 A1
20080009859 Auth et al. Jan 2008 A1
20080015563 Hoey et al. Jan 2008 A1
20080015569 Saadat et al. Jan 2008 A1
20080027464 Moll et al. Jan 2008 A1
20080033241 Peh et al. Feb 2008 A1
20080057106 Erickson et al. Mar 2008 A1
20080058590 Saadat et al. Mar 2008 A1
20080058650 Saadat et al. Mar 2008 A1
20080058836 Moll et al. Mar 2008 A1
20080097476 Peh et al. Apr 2008 A1
20080183081 Lys et al. Jul 2008 A1
20080214889 Saadat et al. Sep 2008 A1
20080228032 Starksen et al. Sep 2008 A1
20080234834 Meade et al. Sep 2008 A1
20080275300 Rothe et al. Nov 2008 A1
20080287790 Li Nov 2008 A1
20080287805 Li Nov 2008 A1
20080319258 Thompson Dec 2008 A1
20090030276 Saadat et al. Jan 2009 A1
20090030412 Willis et al. Jan 2009 A1
20090048480 Klenk et al. Feb 2009 A1
20090054805 Boyle, Jr. Feb 2009 A1
20090062790 Malchano et al. Mar 2009 A1
20090062871 Chin et al. Mar 2009 A1
20090076489 Welches et al. Mar 2009 A1
20090082623 Rothe et al. Mar 2009 A1
20090125022 Saadat et al. May 2009 A1
20090143640 Saadat et al. Jun 2009 A1
20090187074 Saadat et al. Jul 2009 A1
20090203962 Miller et al. Aug 2009 A1
20090221871 Peh et al. Sep 2009 A1
20090227999 Willis et al. Sep 2009 A1
20090264727 Markowitz et al. Oct 2009 A1
20090267773 Markowitz et al. Oct 2009 A1
20090326572 Peh et al. Dec 2009 A1
20100004506 Saadat Jan 2010 A1
20100004633 Rothe et al. Jan 2010 A1
20100004661 Verin et al. Jan 2010 A1
20100130836 Malchano et al. May 2010 A1
20110060227 Saadat Mar 2011 A1
20110060298 Saadat Mar 2011 A1
20110144576 Rothe et al. Jun 2011 A1
20110196237 Pelissier Aug 2011 A1
20120016221 Saadat et al. Jan 2012 A1
20120059366 Drews et al. Mar 2012 A1
20120095332 Nitta Apr 2012 A1
20120150046 Watson et al. Jun 2012 A1
20130131448 Saadat et al. May 2013 A1
20130172745 Choi Jul 2013 A1
20140012074 Vazales et al. Jan 2014 A1
20140114129 Peh et al. Apr 2014 A1
20150094577 Saadat et al. Apr 2015 A1
20150094582 Tanaka Apr 2015 A1
20150190036 Saadat Jul 2015 A1
20150250382 Saadat et al. Sep 2015 A1
20150366440 Rothe et al. Dec 2015 A1
20160038005 Saadat et al. Feb 2016 A1
20160095501 Saadat et al. Apr 2016 A1
20160227989 Saadat et al. Aug 2016 A1
20160361040 Tanaka Dec 2016 A1
20170071460 Miller et al. Mar 2017 A1
20180000314 Saadat et al. Jan 2018 A1
20190008360 Peh et al. Jan 2019 A1
20190014975 Saadat et al. Jan 2019 A1
20190021577 Peh et al. Jan 2019 A1
20190046013 Saadat et al. Feb 2019 A1
20190125166 Saadat May 2019 A1
20190307331 Saadat et al. Oct 2019 A1
20190343373 Saadat et al. Nov 2019 A1
20200000319 Saadat et al. Jan 2020 A1
20200054200 Saadat et al. Feb 2020 A1
20200069166 Miller et al. Mar 2020 A1
Foreign Referenced Citations (50)
Number Date Country
2853466 Jun 1979 DE
10028155 Dec 2000 DE
0283661 Sep 1988 EP
0301288 Feb 1989 EP
0842673 May 1998 EP
S5993413 May 1984 JP
S59181315 Oct 1984 JP
H01221133 Sep 1989 JP
H03284265 Dec 1991 JP
H05103746 Apr 1993 JP
H06507809 Sep 1994 JP
H0951897 Feb 1997 JP
H11299725 Nov 1999 JP
2001504363 Apr 2001 JP
2001258822 Sep 2001 JP
WO-9221292 Dec 1992 WO
WO-9407413 Apr 1994 WO
WO-9503843 Feb 1995 WO
WO-9740880 Nov 1997 WO
WO-9818388 May 1998 WO
WO-0024310 May 2000 WO
WO-0149356 Jul 2001 WO
WO-0172368 Oct 2001 WO
WO-0230310 Apr 2002 WO
WO-03037416 May 2003 WO
WO-03039350 May 2003 WO
WO-03053491 Jul 2003 WO
WO-03073942 Sep 2003 WO
WO-03101287 Dec 2003 WO
WO-2004043272 May 2004 WO
WO-2004080508 Sep 2004 WO
WO-2005070330 Aug 2005 WO
WO-2005077435 Aug 2005 WO
WO-2005081202 Sep 2005 WO
WO-2006017517 Feb 2006 WO
WO-2006024015 Mar 2006 WO
WO-2006083794 Aug 2006 WO
WO-2006091597 Aug 2006 WO
WO-2006126979 Nov 2006 WO
WO-2007067323 Jun 2007 WO
WO-2007079268 Jul 2007 WO
WO-2007133845 Nov 2007 WO
WO-2007134258 Nov 2007 WO
WO-2008015625 Feb 2008 WO
WO-2008021994 Feb 2008 WO
WO-2008021997 Feb 2008 WO
WO-2008021998 Feb 2008 WO
WO-2008024261 Feb 2008 WO
WO-2008079828 Jul 2008 WO
WO-2009112262 Sep 2009 WO
Non-Patent Literature Citations (92)
Entry
Avitall B., et al., “Right-Sided Driven Atrial Fibrillation in a Sterile Pericarditis Dog Model,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
Avitall, et al. “A Catheter System to Ablate Atrial Fibrillation in a Sterile Pericarditis Dog Model,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
Avitall, “Vagally Mediated Atrial Fibrillation in a Dog Model can be Ablated by Placing Linear Radiofrequency Lesions at the Junction of the Right Atrial Appendage and the Superior Vena Cava,” Pacing and Clinical Electrophysiology, 1995, vol. 18, pp. 857.
Baker B.M., et al., “Nonpharmacologic Approaches to the Treatment of Atrial Fibrillation and Atrial Flutter,” Journal of Cardiovascular Electrophysiology, 1995, vol. 6 (10 Pt 2), pp. 972-978.
Bhakta D., et al., “Principles of Electroanatomic Mapping,” Indian Pacing and Electrophysiology Journal, 2008, vol. 8 (1), pp. 32-50.
Bidoggia H., et al., “Transseptal Left Heart Catheterization: Usefulness of the Intracavitary Electrocardiogram in the Localization of the Fossa Ovalis,” Cathet Cardiovasc Diagn, 1991, vol. 24 (3), pp. 221-225, PMID: 1764747 [online], [retrieved Feb. 15, 2010]. Retrieved from the Internets:<URL: http://www.ncbi.nlm.nih.gov/sites/entrez>.
Bredikis J.J., et al., “Surgery of Tachyarrhythmia: Intracardiac Closed Heart Cryoablation,” Pacing and Clinical Electrophysiology, 1990, vol. 13 (Part 2), pp. 1980-1984.
Communication from the Examining Division for Application No. EP06734083.6 dated Nov. 12, 2010, 3 pages.
Communication from the Examining Division for Application No. EP06734083.6 dated Oct. 23, 2009, 1 page.
Communication from the Examining Division for Application No. EP08746822.9 dated Jul. 13, 2010, 1 page.
Co-pending U.S. Appl. No. 61/286,283, filed Dec. 14, 2009.
Co-pending U.S. Appl. No. 61/297,462, filed Jan. 22, 2010.
Cox J.L., “Cardiac Surgery for Arrhythmias,” Journal of Cardiovascular Electrophysiology, 2004, vol. 15, pp. 250-262.
Cox J.L., et al., “Five-Year Experience With the Maze Procedure for Atrial Fibrillation,” The Annals of Thoracic Surgery, 1993, vol. 56, pp. 814-824.
Cox J.L., et al., “Modification of the Maze Procedure for Atrial Flutter and Atrial Fibrillation,” The Journal of Thoracic and Cardiovascular Surgery, 1995, vol. 110, pp. 473-484.
Cox J.L., “The Status of Surgery for Cardiac Arrhythmias,” Circulation, 1985, vol. 71, pp. 413-417.
Cox J.L., “The Surgical Treatment of Atrial Fibrillation,” The Journal of Thoracic and Cardiovascular Surgery, 1991, vol. 101, pp. 584-592.
Elvan A., et al., “Radiofrequency Catheter Ablation of the Atria Reduces Inducibility and Duration of Atrial Fibrillation in Dogs,” Circulation, vol. 91, 1995, pp. 2235-2244 [online], [retrieved Feb. 4, 2013], Retrieved from the Internet:<URL: http://circ.ahajournals.org/cgi/content/full/91/8/2235>.
Elvan A., et al., “Radiofrequency Catheter Ablation (RFCA) of the Atria Effectively Abolishes Pacing Induced Chronic Atrial Fibrillation,” Pacing and Clinical Electrophysiology, 1995, vol. 18, pp. 856.
Elvan, et al., “Replication of the ‘Maze’ Procedure by Radiofrequency Catheter Ablation Reduces the Ability to Induce Atrial Fibrillation,” Pacing and Clinical Electrophysiology, 1994, vol. 17, pp. 774.
European Search Report for Application No. EP07799466.3 dated Nov. 18, 2010, 9 pages.
European Search Report for Application No. EP08746822.9 dated Mar. 29, 2010, 7 Pages.
Examination Communication for Application No. EP06734083.6 dated May 18, 2010, 3 Pages.
Extended European Search Report for Application No. EP06734083.6 dated Jul. 1, 2009, 6 pages.
Extended European search report for Application No. EP20070758716 dated Feb. 28, 2011, 8 Pages.
Extended European search report for Application No. EP20070799466 dated Nov. 18, 2010, 9 Pages.
Fieguth H.G., et al., “Inhibition of Atrial Fibrillation by Pulmonary Vein Isolation and Auricular Resection—Experimental Study in a Sheep Model,” The European Journal of Cardio-Thoracic Surgery, 1997, vol. 11, pp. 714-721.
Final Office Action dated Mar. 1, 2010 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Final Office Action dated Jun. 2, 2011 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Final Office Action dated Oct. 5, 2010 for U.S. Appl. No. 11/810,850, filed Jun. 7, 2007.
Final Office Action dated May 12, 2011 for U.S. Appl. No. 11/775,771, filed Jul. 10, 2007.
Final Office Action dated Sep. 16, 2010 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Hoey M.F., et al., “Intramural Ablation Using Radiofrequency Energy Via Screw-Tip Catheter and Saline Electrode,” Pacing and Clinical Electrophysiology, 1995, vol. 18, Part II, 487.
Huang, “Increase in the Lesion Size and Decrease in the Impedance Rise with a Saline Infusion Electrode Catheter for Radiofrequency,” Circulation, 1989, vol. 80 (4), II-324.
International Search Report and Written Opinion for Application No. PCT/US2007/073184, dated Aug. 12, 2012, 7 pages.
International Search Report for Application No. PCT/US2006/003288, dated Aug. 9, 2007, 1 page.
International Search Report for Application No. PCT/US2007/064195, dated Dec. 7, 2007, 1 page.
International Search Report for Application No. PCT/US2007/071226, dated Sep. 4, 2008, 1 page.
International Search Report for Application No. PCT/US2007/077429, dated Apr. 7, 2008, 1 page.
Moser K.M ., et al., “Angioscopic Visualization of Pulmonary Emboli,” Chest, 1980, vol. 77 (2), pp. 198-201.
Nakamura F., et al., “Percutaneous Intracardiac Surgery With Cardioscopic Guidance,” SPIE, 1992, vol. 1642, pp. 214-216.
Non-Final Office Action dated Jun. 7, 2011 for U.S. Appl. No. 12/323,281, filed Nov. 25, 2008.
Non-Final Office Action dated Aug. 8, 2011 for U.S. Appl. No. 12/464,800, filed May 12, 2009.
Non-Final Office Action dated Jun. 8, 2009 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/961,950, filed Dec. 20, 2007.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/961,995, filed Dec. 20, 2007.
Non-Final Office Action dated May 9, 2011 for U.S. Appl. No. 11/962,029, filed Dec. 20, 2007.
Non-Final Office Action dated Jun. 10, 2010 for U.S. Appl. No. 11/560,742, filed Nov. 16, 2006.
Non-Final Office Action dated Apr. 11, 2011 for U.S. Appl. No. 11/763,399, filed Jun. 14, 2007.
Non-Final Office Action dated Mar. 11, 2011 for U.S. Appl. No. 11/848,202, filed Aug. 30, 2007.
Non-Final Office Action dated May 11, 2011 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Non-Final Office Action dated Apr. 12, 2011 for U.S. Appl. No. 12/499,011, filed Jul. 7, 2009.
Non-Final Office Action dated Jan. 14, 2010 for U.S. Appl. No. 11/828,267, filed Jul. 25, 2007.
Non-Final Office Action dated Dec. 16, 2010 for U.S. Appl. No. 12/117,655, filed May 8, 2008.
Non-Final Office Action dated Mar. 16, 2010 for U.S. Appl. No. 11/810,850, filed Jun. 7, 2007.
Non-Final Office Action dated Feb. 18, 2011 for U.S. Appl. No. 12/947,198, filed Nov. 16, 2010.
Non-Final Office Action dated Feb. 18, 2011 for U.S. Appl. No. 12/947,246, filed Nov. 16, 2006.
Non-Final Office Action dated May 20, 2011 for U.S. Appl. No. 11/775,819, filed Jul. 10, 2007.
Non-Final Office Action dated May 20, 2011 for U.S. Appl. No. 11/877,386, filed Oct. 23, 2007.
Non-Final Office Action dated Jul. 21, 2010 for U.S. Appl. No. 11/687,597, filed Mar. 16, 2007.
Non-Final Office Action dated Apr. 22, 2011 for U.S. Appl. No. 12/367,019, filed Feb. 6, 2009.
Non-Final Office Action dated May 23, 2011 for U.S. Appl. No. 11/775,837, filed Jul. 10, 2007.
Non-Final Office Action dated Nov. 24, 2010 for U.S. Appl. No. 11/848,429, filed Aug. 31, 2007.
Non-Final Office Action dated Nov. 24, 2010 for U.S. Appl. No. 12/464,800, filed May 12, 2009.
Non-Final Office Action dated Apr. 25, 2011 for U.S. Appl. No. 11/959,158, filed Dec. 18, 2007.
Non-Final Office Action dated Feb. 25, 2010 for U.S. Appl. No. 11/259,498, filed Oct. 25, 2005.
Non-Final Office Action dated Feb. 25, 2011 for U.S. Appl. No. 11/848,207, filed Aug. 30, 2007.
Non-Final Office Action dated Apr. 26, 2011 for U.S. Appl. No. 11/848,532, filed Aug. 31, 2007.
Non-Final Office Action dated Apr. 27, 2011 for U.S. Appl. No. 11/828,281, filed Jul. 25, 2007.
Non-Final Office Action dated Aug. 27, 2010 for U.S. Appl. No. 11/775,771, filed Jul. 10, 2007.
Non-Final Office Action dated Dec. 27, 2010 for U.S. Appl. No. 12/026,455, filed Feb. 5, 2008.
Notice of Allowance dated Feb. 3, 2011 for U.S. Appl. No. 11/560,732, filed Nov. 16, 2006.
Notice of Allowance dated Jun. 13, 2011 for Japanese Application No. 2007-554156 filed Jan. 30, 2006.
Notice of Allowance dated Nov. 15, 2010 for U.S. Appl. No. 11/259,498, filed Oct. 25, 2005.
Notice of Allowance dated Nov. 15, 2010 for U.S. Appl. No. 11/560,742, filed Nov. 16, 2006.
Notice of Allowance dated Feb. 24, 2011 for U.S. Appl. No. 11/560,732, filed Mar. 16, 2007.
Notice of Allowance dated Feb. 24, 2011 for U.S. Appl. No. 11/687,597, filed Mar. 16, 2007.
Office Action dated Feb. 15, 2011 for Japanese Application No. 2007-554156 filed Jan. 30, 2006.
Office Action dated Apr. 27, 2011 for Japanese Application No. 2009-500630 filed Mar. 16, 2007.
Pappone C., et al., “Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia,” Circulation, 2000, vol. 102, pp. 2619-2628.
Sethi K.K., et al., “Transseptal catheterization for the electrophysiologist: modification with a ‘view’,” Journal of Interventional Cardiac Electrophysiology, 2001, vol. 5 (1), pp. 97-99.
Tse HF., et al., “Angiogenesis in Ischaemic Myocardium by Intramyocardial Autologous Bone Marrow Mononuclear Cell Implantation,” Lancet, 2003, vol. 361, pp. 47-49.
Supplemental European Search Report for Application No. EP07758716 dated Feb. 28, 2011, 8 Pages.
Supplementary European search report for Application No. EP07812146.4 dated Nov. 18, 2010, 8 Pages.
Supplementary European Search Report for Application No. EP07841754, dated Jun. 30, 2010, 6 pages.
Thiagalingam A., et al., “Cooled Needle Catheter Ablation Creates Deeper and Wider Lesions than Irrigated Tip Catheter Ablation,” Journal of Cardiovascular Electrophysiology, 2005, vol. 16(5), pp. 1-8.
Uchida Y., “Developmental History of Cardioscopes”, in: Coronary Angioscopy, Chapter 19, Futura Publishing Company, Inc., 2001, pp. 187-197.
Willkampf F.H., et al., “Radiofrequency Ablation with a Cooled Porous Electrode Catheter,” JACC, Abstract, 1988, vol. 11 (2), pp. 17A.
Written Opinion for Application No. PCT/US2006/003288, dated Aug. 9, 2007, 6 pages.
Written Opinion for Application No. PCT/US2007/064195, dated Dec. 7, 2007, 5 pages.
Written Opinion for Application No. PCT/US2007/071226, dated Sep. 4, 2008, 4 page.
Written Opinion for Application No. PCT/US2007/077429, dated Apr. 7, 2008, 5 pages.
Related Publications (1)
Number Date Country
20180228350 A1 Aug 2018 US
Provisional Applications (1)
Number Date Country
60824423 Sep 2006 US
Divisions (1)
Number Date Country
Parent 11848207 Aug 2007 US
Child 15956068 US